0001213900-24-003308.txt : 20240112 0001213900-24-003308.hdr.sgml : 20240112 20240112150431 ACCESSION NUMBER: 0001213900-24-003308 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20240112 DATE AS OF CHANGE: 20240112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Genufood Energy Enzymes Corp. CENTRAL INDEX KEY: 0001510518 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680681158 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56112 FILM NUMBER: 24531813 BUSINESS ADDRESS: STREET 1: 1108 S. BALWAIN AVENUE, SUITE 107 CITY: ARCADIA STATE: CA ZIP: 91007 BUSINESS PHONE: (855) 707-2077 MAIL ADDRESS: STREET 1: 1108 S. BALWAIN AVENUE, SUITE 107 CITY: ARCADIA STATE: CA ZIP: 91007 10-K 1 f10k2023_genufood.htm ANNUAL REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended September 30, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from to

 

Commission File Number 000-56112

 

GENUFOOD ENERGY ENZYMES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada   68-0681158
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

1108 S. Baldwin Avenue, Suite 107

Arcadia, California 91007

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (855) 707-2077

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Name of each exchange on which registered
     

 

Securities registered pursuant to Section 12(g) of the Act:

Common Stock

 

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer  
Smaller reporting company Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No

 

As of January 9, 2024, there were 808,900,041 shares outstanding, $0.001 par value per share, of the registrant’s common stock outstanding. No market value has been computed based upon the fact that no active trading market had been established as of September 30, 2023. 

 

 

 

 

 

 

GENUFOOD ENERGY ENZYMES CORP.

 

FORM 10-K FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2023

 

TABLE OF CONTENTS

 

    Page
PART I  
 
ITEM 1. BUSINESS 1
     
ITEM 1A. RISK FACTORS 3
     
ITEM 1B. UNRESOLVED STAFF COMMENTS 3
     
ITEM 2. PROPERTIES 3
     
ITEM 3. LEGAL PROCEEDINGS 3
     
ITEM 4. MINE SAFETY DISCLOSURES 3
     
PART II
 
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 4
     
ITEM 6. [RESERVED] 5
     
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 5
     
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 10
     
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 10
     
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 10
     
ITEM 9A. CONTROLS AND PROCEDURES 10
     
ITEM 9B. OTHER INFORMATION 12
     
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 12
     
PART III
 
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 13
     
ITEM 11. EXECUTIVE COMPENSATION 15
     
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 18
     
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 19
     
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 19
     
PART IV
 
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 20
     
ITEM 16. FORM 10-K SUMMARY 21
     
SIGNATURES 22
     
POWER OF ATTORNEY 22

 

i

 

 

GENERAL NOTE

 

We refer to our business from the period from inception (June 21, 2010) through approximately mid- to late-2016, as our “historic period”, the business conducted during the historic period as our “original business” and the management of our company during the historic period as “Oliver Lin’s management”.

 

FORWARD-LOOKING STATEMENTS

 

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

 

Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

 

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. Some of the key factors impacting these risks and uncertainties include, but are not limited to:

 

  risks related to our ability to identify, pursue and commence a reverse merger and/or a possible operating business;

 

  our ability to obtain adequate funding to complete a reverse merger or commence a possible operating business and meet our operating expenses on a current basis;

 

  general economic uncertainty, whether as a result of the COVID-19 pandemic or otherwise;

 

  delays in our ability to obtain any necessary business licenses and permits, and commence business operations, whether as a result of the COVID-19 pandemic or otherwise; and

 

  current and longer-term economic and other impacts of the COVID-19 pandemic on our operations, results of operations and financial condition, including without limitation changes in consumer spending patterns for non-essential products, resulting from the economic crisis caused by lockdown, shelter-in-place, stay-at-home or similar orders instituted as a result of the pandemic, or otherwise.

 

ii

 

 

ITEM 1. BUSINESS 

 

The discussion of the business of Genufood Energy Enzymes Corp. and its wholly-owned subsidiary (“Genufood” “we” or the “Company”), is as of the date of filing this report, unless otherwise indicated.

 

Original Business

 

During our historic period, we were a start-up company whose main focus was to promote, market, distribute and export a range of enzyme products manufactured in the United States for sale for human and animal consumption in certain Asian markets, including the Association of Southeast Asian Nations (“ASEAN”). Our objective was to commence marketing and distribution of a range of enzyme products for human and animal consumption to sole country distributors, wholesalers, dealers and retailers, as well as to the general public following a Multi-Level Marketing - Franchise Investor Dealer Related (MLM-FIDR) concept, beginning in Taiwan, and then China, Hong Kong, Macau, Thailand, Malaysia, Singapore and Sri Lanka.

 

At some point, which we believe may have occurred approximately mid-to late-2016, Oliver Lin’s management ceased operating our original business. We have not generated any revenue from operations since that time.

 

Genufood Energy Enzymes Corp. was incorporated in Nevada on June 21, 2010. Our principal place of business is located at 1108 S. Baldwin Avenue, Suite 107, Arcadia, California 91007 and our telephone number is (855) 707-2077. Our website is www.geecenzymes.com. No part of our website is incorporated into this report.

 

Recent Developments

 

On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement our new business plan in such industry. On August 16, 2022, we formally announced our intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. We intend to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

 

On October 26, 2022, we entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow us to install our electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, we have agreed to share our revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.

 

As of September 30, 2023, we had two sites under construction for charging stations and three sites under planning for future construction. We are actively negotiating and searching for additional sites for future development.

 

At this time, we reserve the right to further change our business plan at any time.

 

1

 

 

Hukui Investment

 

In late September 2020, we announced that we and Hukui Biotechnology Corporation (“Hukui”) had entered into a Series C Preferred Shares Subscription Agreement dated September 23, 2020 (the “Hukui Agreement”), pursuant to which we have agreed to purchase an aggregate 200,000 shares of Hukui’s Series C Preferred Stock (“Series C Preferred Shares”) at $10.00 per share, for an aggregate investment of $2,000,000.

 

The Hukui Agreement provided that we would purchase the Series C Preferred Shares in three tranches, through a date on or before June 30, 2022, as follows:

 

  The first tranche is 80,000 Series C Preferred Shares in the amount of $800,000 (the “First Tranche Investment”), such shares having been purchased by us on December 15, 2020 (the “First Tranche Closing”);

 

  The second tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Second Tranche Investment”), such shares having been purchased by us on June 25, 2021 (the “Second Tranche Closing”); and

 

  The third tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Third Tranche Investment”), such shares to have been purchased on or before June 30, 2022 (the “Third Tranche Closing”).

 

Following the end of our 2021 fiscal year, an individual and resident of the Republic of China (the “Purchaser”), Hukui and us entered into a Stock Purchase Agreement dated as of November 17, 2021 (the “Stock Purchase Agreement”), pursuant to which we agreed to sell the 140,000 shares of Hukui’s Series C Preferred Stock that we had purchased in the First Tranche Closing and the Second Tranche Closing (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

 

As a result of our original purchase of the first 80,000 of the Hukui Shares on December 15, 2020, together with certain other factors, we may have been deemed to be an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). To the extent that we may have been deemed to be an investment company, we have been relying on Rule 3a-2 promulgated under the Investment Company Act, allowing us to terminate our investment company status on or before December 15, 2021, the first anniversary of our purchase of the first 80,000 of the Hukui Shares, without having to register and be regulated as an investment company.

 

Believing that it is not in the best interests of the Company and its shareholders to register and be regulated as an investment company under the Investment Company Act, we explored different lawful means by which we could terminate our potential investment company status. We determined that the only viable option to terminate our potential investment company status and lawfully avoid registration and regulation under the Investment Company Act was to sell the Hukui Shares on or before the December 15, 2021, deadline.

 

After making diligent efforts to seek a purchaser of the Hukui Shares, we received three all-cash offers to purchase the Hukui Shares. We accepted the offer of the Purchaser, which was the highest of the three all-cash offers that we received.

 

We had purchased the Hukui Shares in two tranches, on December 15, 2020, and June 30, 2021, pursuant to the Hukui Agreement, at $10.00 per share, for an aggregate purchase price of $1,400,000. We sold the Hukui Shares at $2.50 per share, for a total price of $350,000, resulting in a loss of $1,050,000. We recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021. See Note 4 to the Consolidated Financial Statements.

 

On December 17, 2021, Hukui and us entered into an Agreement (the “Termination Agreement”), pursuant to which our obligation to make the Third Tranche Investment was terminated and the Hukui Agreement was terminated. As a result, we have no continuing contractual obligation to make any investment in Hukui.

 

2

 

 

With the sale of the Hukui Shares, we believe that we are no longer deemed to be an investment company as defined in the Investment Company Act and, accordingly, we are not required to register and be regulated as an investment company thereunder. Additionally, with the execution of the Termination Agreement, the possibility that we could again become an inadvertent investment company under the Investment Company Act has been removed.

 

We have decided to expand our business in the area of electric vehicle supply equipment (“EVSE”), and we will need to raise capital to pursue such a business. There are no commitments in place to fund such business and no guarantee can be given that we will be able to secure such funding on terms that are favorable to us, or at all .

 

Employees

 

As of December 31, 2023, we had 2 part time employees and 1 full time employee. Our employees were based in both Taiwan and USA.

 

ITEM 1A. RISK FACTORS

 

Not required for smaller reporting companies.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not required for smaller reporting companies.

 

ITEM 2. PROPERTIES

 

Our principal executive offices are located at 1108 S. Baldwin Avenue, Suite 107, Arcadia, California 91007. The arrangement is on a month-to-month basis at a cost of $200 per month.

 

ITEM 3. LEGAL PROCEEDINGS

 

There are presently no material pending legal proceedings to which we are a party or as to which any of our property is subject, and no such proceedings are known to us to be threatened or contemplated against us.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

3

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Our common stock (“Common Stock”) is not traded on any stock exchange and is occasionally quoted on the OTC Pink Market. As of December 31, 2023, there were approximately 261 record holders of our Common Stock.

 

Dividend Policy

 

We have not paid any cash dividends to date and do not anticipate or contemplate paying dividends in the foreseeable future. It is the present intention of management to utilize all available funds for the execution of our business model.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

We have not authorized the issuance of, or issued, any securities under a retirement, pension, profit sharing, stock option or other equity compensation plans.

 

Recent Sales of Unregistered Securities

 

On February 24, 2023, we sold 375,000,000 shares of our Common Stock at a purchase price of $0.001 per share, for gross and net proceeds of $375,000, before allocating certain expenses associated with the offering in the amount of $13,000 as adjusted paid-in capital. See Note 6 to the Financial Statements.

 

On March 31, 2023, we issued an aggregate of 134,213,120 share of our Common Stock to certain of our current and former directors, officers, employees, and a consultant, who converted accrued and unpaid compensation in the aggregate amount of $134,213 at a rate of $0.001 per share of our Common Stock.

 

We offered and issued all of the foregoing securities under the exemption from registration provided by Section 4(a)(2) of the Securities Act, and/or Regulation D or Regulation S promulgated thereunder.

 

4

 

 

ITEM 6. [RESERVED]

 

Not required for smaller reporting companies.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 

 

This discussion should be read in conjunction with the Company’s audited consolidated financial statements, including the Notes thereto, for the years ended September 30, 2022 and September 30, 2023, beginning on Page F-1.

 

Overview

 

On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

 

On October 26, 2022, we entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow us to install our electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, we have agreed to share our revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.

 

As of December 31, 2022, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging Stations at the three confirmed sites. As of December 31, 2022, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.

 

As of February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities. The Company expects to install up to a total of 10 charging units for the first 2 sites, and have them operational in October of 2023.

 

5

 

 

As of September 30, 2023, the Company has began constructions on two sites with total of 10 charging units and three sites with signed agreement under planning.

 

Hukui Investment

 

Hukui Biotechnology Corporation (“Hukui”) and we entered into a Series C Preferred Shares Subscription Agreement dated September 23, 2020 (the “Hukui Agreement”), pursuant to which we agreed to purchase an aggregate 200,000 shares of Hukui’s Series C Preferred Stock (the “Series C Preferred Shares”) at $10.00 per share, for an aggregate investment of $2,000,000.

 

The Hukui Agreement provided that we would purchase the Series C Preferred Shares in three tranches, through a date on or before June 30, 2022, as follows:

 

  The first tranche is 80,000 Series C Preferred Shares in the amount of $800,000 (the “First Tranche Investment”), such shares having been purchased by us on December 15, 2020 (the “First Tranche Closing”);

 

  The second tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Second Tranche Investment”), such shares having been purchased by us on June 25, 2021 (the “Second Tranche Closing”); and

 

  The third tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Third Tranche Investment”), such shares to have been purchased on or before June 30, 2022 (the “Third Tranche Closing”).

 

An individual and resident of the Republic of China (the “Purchaser”), Hukui and we entered into a Stock Purchase Agreement dated as of November 17, 2021 (the “Stock Purchase Agreement”), pursuant to which we agreed to sell the 140,000 shares of Hukui’s Series C Preferred Stock that we had purchased in the First Tranche Closing and the Second Tranche Closing (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

 

On December 17, 2021, Hukui and we entered into an Agreement (the “Termination Agreement”), pursuant to which our obligation to make the Third Tranche Investment was terminated and the Hukui Agreement was terminated. As a result, we have no continuing contractual obligation to make any investment in Hukui.

 

Results of Operations

 

Year Ended September 30, 2023 compared to the Year Ended September 30, 2022

 

Revenues

 

We did not generate any revenues during the years ended September 30, 2023 and 2022.

 

6

 

 

Operating Expenses

 

We incurred total operating expenses of $432,296 and $348,845 for the years ended September 30, 2023 and 2022, respectively. Our operating expenses consist of business development expenses, legal fees, other professional fees, payroll expenses, stock-based compensation, rent, bank charges, and transfer agent fees. The increase in operating expenses for the year ended September 30, 2023 compared to the same period ended in 2022 was primarily due to increase in payroll expenses, stock-based compensation as well as business development expenses related to the installation of charging stations.

 

Other expense

 

During the year ended September 30, 2023, we incurred $195,406 other expenses mainly due to interest incurred for unpaid penalty from IRS and the loss on disposal of our Singapore subsidiary of $192,365. During the year ended September 30, 2022, we incurred $3,823 other expenses mainly due to interest incurred for unpaid penalty from IRS.

 

Net Loss

 

As a result of the above, our net loss increased from $352,668 in the year ended September 30, 2022 to $627,702 in the same period ended in 2023.

 

Effect of the COVID-19 Pandemic on our Business

 

While our liquidity and capital resources are severely limited and present serious obstacles to starting a business, these limitations are unrelated to the COVID-19 pandemic and resulting global economic crisis.

 

Our personnel are in Taiwan, which has been relatively less affected by the pandemic compared to many other countries in Asia, Europe and the United States.

 

Depending upon the extent and duration of the pandemic and the resulting global economic crisis, these conditions may have an adverse impact on our ability to raise capital and commence any business we may pursue.

 

Liquidity and Capital Resources

 

Working Capital

 

   September 30,   September 30, 
   2023   2022 
Current Assets  $134,111   $150,893 
Current Liabilities   115,616    205,016 
Working Capital (Deficit)  $18,495   $(54,123)

 

As of September 30, 2023, we had current assets of $134,111 and a working capital surplus of $18,495. In comparison, as of September 30, 2022, we had current assets of $150,893 and a working capital deficit of $54,123.

 

We had $115,616 in total current liabilities as of September 30, 2023, consisting of $100,849 in accounts payable, $37 in accrued expenses, and $14,730 due to related parties. This is compared to total current liabilities of $205,016 in total current liabilities as of September 30, 2022, consisting of $102,185 in accounts payable and $102,831 due to related parties. The decrease in due to related parties was primarily due to unpaid compensation to officers and directors repaid by shares.

 

We had total stockholders’ equity of $53,720 and an accumulated deficit of $10,503,191 as of September 30, 2023. In comparison, we had a total stockholders’ deficit of $83,349 and an accumulated deficit of $9,875,489 as of September 30, 2022.

 

7

 

 

Cash Flows

 

   Year ended
September 30,
2023
   Year ended
September 30,
2022
 
Cash flows used in operating activities  $(305,025)  $(222,828)
Cash flows provided by (used in) investing activities   (67,451)   350,000 
Cash flows provided by financing activities   362,000    - 
Effect of exchange rate changes on cash   -    (43)
Net increase in cash during period  $(10,476)  $127,129 

 

During the year ended September 30, 2023, we used $305,025 of cash in operating activities which was attributable primarily to our net loss of $627,702 offset by loss on disposal of subsidiary, stock-based compensation, and change in operating assets and liabilities of $322,677. In comparison, during the year ended September 30, 2022, we used $222,828 of cash in operating activities which was attributable primarily to our net loss of $352,668 offset by stock-based compensation and change in operating assets and liabilities of $129,840.

 

During the year ended September 30, 2023, we used $67,451 of cash investing activity in purchase of equipment. We received $350,000 in payment for the sale of 140,000 Hukui Shares during the year ended September 30, 2022.

 

During the year ended September 30, 2023, we received $362,000, net of directly associated legal fees from private offering of our Common Stock. During the year ended September 30, 2022, we did not have any financing activity.

 

There is substantial doubt that we can continue as an ongoing business for the next twelve months unless we obtain additional capital to pay our expenses as they become due. We do not anticipate any significant additional revenue until and unless we begin to execute our plan of operations involving the start of our new electric vehicle charging station business. There is no assurance that we will ever reach that stage. The consolidated financial statements presented herein do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that we cannot continue as a going concern.

 

Our ability to continue as a going concern is dependent upon our ability to successfully execute our business plan and generate profitable operations in the future, and, until and unless we achieve that, to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operation as and when they become due. To date, our capital requirements have primarily been funded by shareholders through the purchase of our Common Stock in private offerings and short-term borrowings from a former officer and another shareholder.

 

The Company sold 140,000 Hukui Shares for $350,000 cash on November 19, 2021 and received $362,000 from private placement during the nine months ended June 30, 2023. The proceeds have been used for operation expenses.

 

Contractual Obligations

 

We do not have material contractual obligations and commitments. We only have one lease that is renewed on a month-to-month basis.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2023, we had not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. As of September 30, 2023, we had not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our condensed consolidated financial statements. Furthermore, as of September 30, 2023, we had not had any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. As of September 30, 2023, we had not had any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

 

8

 

 

Critical accounting policies and estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to income taxes, and the valuation of equity transactions. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. For the years ended September 30, 2023, and 2022, no significant estimates and assumptions have been made in the consolidated financial statements. The following are some of the critical accounting policies in relation to the preparation of the consolidated financial statements. For a full summary of our critical accounting policies, please refer to Note 2 to the Consolidated Financial Statements.

 

Stock-Based Compensation

 

We account for stock-based compensation in which we obtain employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires us to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

 

Recent accounting pronouncements

 

We do not expect that the adoption of recently issued accounting pronouncements will have a material impact on our financial position, results of operations, or cash flows. For a full summary of recent accounting pronouncements, please refer to Note 2 to the Consolidated Financial Statements.

 

9

 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting companies.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The full text of our audited consolidated financial statements begins on page F-1 of this annual report.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

On February 23, 2022, (i) DYH & Company (“DYH”) resigned as the independent registered public accounting firm of the Company; and (ii) the Board of Directors of the Company, which acts as the audit committee, engaged KCCW Accountancy Corp. (“KCCW”) as the Company’s new independent registered public accounting firm.

 

The reports of DYH on the consolidated financial statements of the Company as of and for the years ended September 30, 2020, and 2021 did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principle.

 

During the years ended September 30, 2020 and 2021 and through February 23, 2022, there were no disagreements with DYH on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of DYH, would have caused DYH to make reference to the subject matter of the disagreement in its reports on the Company’s consolidated financial statements for such years.

 

The Company has provided DYH with a copy of the disclosures it is making herein and has requested that DYH furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not DYH agrees with the above statements. A copy of such letter is provided herewith as Exhibit 16.1.

 

No consultations occurred between the Company and KCCW during the years ended September 30, 2020 and 2021 and through February 23, 2022, regarding either (i) the application of accounting principles to a specific completed or proposed transaction, the type of audit opinion that might be rendered on the Company’s financial statements, or other written or oral information provided that was an important factor considered by the Company in reaching a decision as to an accounting, auditing, or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K, or a “reportable event,” as that term is defined in Item 304(a)(1)(v) of Regulation S-K.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that the information relating to our Company, including our consolidated subsidiaries, required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of the evaluation date, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting, as described below.

 

10

 

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of management, including our chief executive officer and chief financial officer, we conducted an evaluation of the design and operating effectiveness of our internal controls over financial reporting based on the framework in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

 

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:

 

Inadequate Segregation of Duties: We have an inadequate number of personnel to properly implement control procedures.

 

Comingling of funds: We do not have adequate control of our petty cash, resulting in the comingling of our petty cash with the nominal account holder’s personal funds.

 

Lack of Adequate Staffing: We do not have adequate in-house accounting personnel and expertise in key positions, resulted in overly relying on outside consultants in preparing financial statements and other required disclosures by the Securities and Exchange Commission.

 

Ineffective oversight: We do not exercise effective oversight and monitoring procedures designed and implemented to certain control activities.

 

Overly relied on outside professionals: We are unable to prepare internally financial statements and relied on outside professional consultants to prepare financial statements and adequate disclosures.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As a result of the material weaknesses in internal control over financial reporting identified above, management concluded that the Company’s internal control over financial reporting was not effective as of September 30, 2022 based on the criteria set forth in “Internal Control-Integrated Framework” issued by COSO.

 

Due to the nature of the material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected. The material weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s consolidated financial statements at and for the year ended September 30, 2023.

 

11

 

 

Management’s Plan for Remediation 

 

Management has discussed the material weaknesses noted above with our independent registered public accounting firm. Management is committed to improving its internal controls and, subject to having adequate financial resources, intends to:

 

increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties to monitor and review until there are sufficient personnel to segregate duties;

 

  consider providing professional courses for our key position personnel;

 

  hire additional employees to realize segregation of duties; and

 

  strengthen management monitoring control over accounting and financial statements preparation processing.

 

However, due to limitation of funds and personnel, we have so far been unable to begin to implement the plan to remediate the material weaknesses noted above.

 

Inherent Limitations on Effectiveness of Controls

 

A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect all control issues or misstatements. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become adequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Changes in Internal Control

 

There have been no changes in our internal control over financial reporting that occurred during the year ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

None.

 

12

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

As of the date of the filing of this Annual Report, our current directors and executive officers and additional information concerning them are as follows:

 

Name   Age   Position
         
David Tang   45   Chief Executive Officer
         
Jui Pin (John) Lin   68   Chairman of the Board, President, and Director
         
Kuang Ming (James) Tsai   73   Director, Chief Financial Officer
         
Wen-Piao (Jack) Lai   71   Director
         
Hsin-Ta (Darren) Su   46   Director
         
Hui-Chuan (Sandra) Lin   39   Director and Secretary

 

David Tang has served as our Chief Executive Officer since July 15, 2022. Prior to joining us, Mr. Tang was a Relationship Manager of Venture Lending Emerging Technologies division at East West Bank in California from 2019 to 2022. Prior to that, Mr. Tang was an advisor to many startups in Hong Kong, including Maxvoice and Maxisense from 2016 to 2019. Mr. Tang was the founder and the Chief Executive Officer of Fontainebleau Partners, a technology startup in Hong Kong from 2012 to 2016. In 2011, Mr. Tang was an Equity Research Analyst at BNP Paribas Securities in Hong Kong and Taipei. In 2009, Mr. Tang was an MBA Consultant for Swire Coca-Cola HK Limited. From 2005 to 2008, Mr. Tang was a Relationship Manager at Manufacturing Bank in California, a Sumitomo Mitsui Banking Corporation subsidiary. From 2004 to 2005, Mr. Tang was a Client Financial Analyst at Citibank in California. Mr. Tang has a bachelor degree in History from University of California, Irvine and a Master of Business Administration degree in Finance from Hong Kong University of Science & Technology. Mr. Tang is currently a mentor at KidsX Accelerator, a network of pediatric experts and innovators founded and administered by Children’s Hospital Los Angeles.

 

Jui Pin (John) Lin has served as our President since July 14, 2022, and Mr. Lin has served as a director since June 17, 2021. He also served as our President from March 4, 2020 to August 1, 2021 and as our Chief Executive Officer from March 18, 2020 to August 1, 2021. Mr. Lin previously served as our President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer, and as a director, from April 18, 2017 to August 4, 2017. From November 1983 to the present, Mr. Lin has served as the President of Risesun Electrical & Industry Co. Ltd. located in Taiwan. From March 1994 to the present, he has served as President of Risesun Electric & Industry (Kunshan) Co. Ltd. located in China. From May 1998 to the present, Mr. Lin has served as the Chairman and Director of Yogo Textile Co. Ltd. located in Bangladesh. From September 2015 to the present, he has served as the President of First Empire Corp. located in Seychelles. From November 2018 to the present, Mr. Lin has served as the President of Rekun Electronic Technology (Kunshan) Corp. located in China. Mr. Lin received a bachelor degree from the Oriental Institute of Technology in Taipei, Taiwan in 1977, where he majored in Textile Engineering.

 

13

 

 

Kuang Ming (James) Tsai has served as our Chief Financial Officer since July 22, 2023, our Chief Operating Officer since July 14, 2022, and has served as a director since June 11, 2018. Mr. Tsai served as our President from June 29, 2018 to March 4, 2020, our Chief Executive Officer from June 29, 2018 to March 18, 2020 and our Chief Financial Officer from September 12, 2018 to March 18, 2020. From July 2017 to June 2018, Mr. Tsai served as the President of YAMA KAWA Bilingual Club, part of District 67 Toastmasters International. From 2010 to 2017, Mr. Tsai was retired, during which period he was an investor of securities. From 2006 to 2010, he served as the President of Blanfield Pty Ltd., an import company. Mr. Tsai received a Bachelor of Arts Degree from National Taiwan University in 1973, majoring in Economics.

 

Wen-Piao (Jack) Lai has served as a director since June 17, 2021. Mr. Lai founded Kuan Dar Textile Co., Ltd., located in Taoyuan City, Taiwan, in 1987 and has served as its President since that time. From January 2016 to December 2017, Mr. Lai served as President of the Alumni Association of Sha-Lu Industrial Vocational Senior High School, from which he graduated in 1967. Mr. Lai has extensive experience in business operations and management through more than 30 years of business management experiences in the company he founded. He also has participated with volunteer firefighting with Taoyuan City Bade Fire Station Squadron in Taoyuan City, Taiwan since 1999.

 

Hsin-Ta (Darren) Su has served as a director since October 29, 2021 and as our IT manager since March 2020. From April 2020 to October 2021, he was a software developer for JC Healthcare Technology Co., Ltd. In Taiwan. From May 2016 to March 2020, he was a software developer Evolve Development Co., Ltd., in Taiwan. Mr. Su received an associate degree of computer engineering in 1998 from Kuang Wu Junior College in Taiwan.

 

Hui-Chuan (Sandra) Lin has served as Secretary since July 15, 2022. Ms Lin was previously a Sales Representative of Tai-Wan Motor Parts Co., Ltd since 2017. Ms. Lin received a Master of Business Administration from the University of Glasgow in 2012. Ms. Lin also received her bachelor’s degree in civil engineering from Chung Yuan Christian University in 2007.

 

None of our directors presently serves as a director of any other public companies. We have not entered into indemnification agreements with our directors, although they have indemnification protection under the laws of the State of Nevada, in which we are incorporated. We do not currently maintain director and officer liability insurance.

 

We believe that what qualifies each of our directors to serve as such is that each of our directors has a good working relationship with our shareholders generally, has been engaged in private raises of capital, which we will require, and has a broad background in business, all of which qualities and attributes could help us in the future.

 

Term of Office

 

Directors hold office until the next annual meeting of our shareholders and until their successors have been duly elected and qualified. Our Bylaws provide that our Board of Directors will consist of no less than one nor more than nine members, as may be set from time to time by our shareholders. Our officers are appointed by, and serve at the discretion of, the Board of Directors.

 

Director Independence

 

Our Board of Directors is currently composed of 5 members, neither of whom qualifies as an independent director in accordance with the published listing requirements of the Nasdaq Stock Market. The Nasdaq independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his or her family members has engaged in various types of business dealings with us.

 

14

 

 

In addition, our Board of Directors has not made a subjective determination as to any of our directors that no relationships exist which, in the opinion of our Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, although such subjective determination is required by Nasdaq requirements. Had our Board of Directors made these determinations, our Board of Directors would have reviewed and discussed information provided by our directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management.

 

Involvement in Certain Legal Proceedings

 

During the past ten years, there have been no events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any director, executive officer, promoter or control person of the Company, including any allegations (not subsequently reversed, suspended or vacated), permanent or temporary injunction, or any other order of any federal or state authority or self-regulatory organization, relating to activities in any phase of the securities, commodities, banking, savings and loan, or insurance businesses in connection with the purchase or sale of any security or commodity, or involving mail or wire fraud in any business.

 

Corporate Governance, Committee Structure and Conflicts of Interest

 

We do not have standing audit, compensation and nominating/corporate governance committee, or committees performing similar functions. We have not adopted a code of ethics. We anticipate that as we become more familiar with the obligations of U.S. public companies, we will implement appropriate corporate governance structures to comply with SEC and/or stock exchange requirements. We intend to comply with all corporate governance requirements applicable to us at this time.

 

Since our Board of Directors does not have standing audit, compensation or nominating/corporate governance committees, or any other committees, the functions that would have been performed by such committees are performed by our Board of Directors as a whole. We do not currently have a director who would satisfy the requirements of being an audit committee financial expert. Our Board of Directors has determined that such committees are not necessary at this time, since the Company is in the early stages of its plan of operations, and there is no active trading of our Common Stock. It should be noted that since, at most, only one of our directors is independent, there is a risk of conflicts of interest arising from time to time. During the next fiscal year, our Board of Directors will monitor whether and when it would be appropriate to diversify the Board of Directors to include independent directors and/or establish Audit, Compensation and/or Nominating/Corporate Governance Committees.

 

Shareholder Communications with the Board of Directors

 

We have not implemented a formal policy or procedure by which our stockholders can communicate directly with our Board of Directors. Nevertheless, our directors welcome the views of our shareholders. During the next fiscal year, our Board of Directors will continue to monitor whether and when it would be appropriate to adopt such a process.

 

ITEM 11. EXECUTIVE COMPENSATION

 

The Summary Compensation Table shows certain compensation information for services rendered in all capacities for the fiscal years ended September 30, 2023 and 2022. Other than as set forth herein, no executive officer’s salary and bonus exceeded $100,000 in any of the applicable years. The following information includes the dollar value of base salaries, bonus awards, the number of stock options granted and certain other compensation, if any, whether paid or deferred.

 

15

 

 

Summary Compensation Table

 

Name and Principal Position   Fiscal
Year
    Salary
($)
    Bonus
($)
    Stock
Awards
($)
    Option
Awards
($)
    All other
compensation
($)
    Total
($)
 
David Tang     2022       31,250       -       -       15,822            -       47,072  
Chief Executive Officer     2023       150,000       -       -       75,000       -       225,000  
                                                         
Wen-Piao (Jack) Lai(1)     2022       22,210       -       -       -       -       22,210  
Director, Former CEO     2023       1,800       -       -       -       -       1,800  
                                                         
Shao-Cheng (Will) Wang(2)     2022       27,600                                       27,600  
      2023       0                                       0  
                                                         
Jin Pin (John) Lin(3)     2022       8,048       -       -       -       -       8,048  
President     2023       9,000       -       -       -       -       9,000  
                                                         
Kuang-Ming (James) Tsai(4)     2022       20,755       -       -       -       -       20,755  
Chief Financial Officer     2023       5,400       -       -       -       -       5,400  
                                                         
Hsin-Ta (Darren) Su(5)     2022       17,189       -       -       -       -       17,189  
Treasurer     2023       15,300       -       -       -       -       15,300  
                                                         
Hui-Chuan (Sandra) Lin(6)     2022       4,529       -       -       -       -       4,529  
Secretary     2023       5,400       -       -       -       -       5,400  

 

1

From September 30, 2021, through September 30, 2022, Mr. Lai was entitled to receive his compensation in the amount of $2,500 per month. Of the total amount of the $22,210 earned by Mr. Lai through September 30, 2022, as executive compensation, $0 was paid and $22,210 was accrued. Mr. Lai converted his accrued amount into 24,010,000 shares of common stock on March 24, 2023.

 

2

34,500,000 shares of Mr. Wang’s accrued and unpaid compensation has been converted to shares of our Common Stock on March 24, 2023. From September 30, 2021, through September 30, 2022, Mr. Wang was entitled to receive his compensation in the amount of $2,300 per month. Of the total amount of the $27,600 earned by Mr. Wang through September 30, 2022, as the former CFO $0 was paid and $27,600 was accrued. Additionally, Mr. Wang has resigned from the Chief Financial Officer position on July 22, 2023.

 

3Mr. Lin served as our President from March 4, 2020, until August 1, 2021 and as our Chief Executive Officer from March 18, 2020 until August 1, 2021. From September 30, 2021, through September 30, 2022, Mr. Lin was entitled to receive his compensation in the amount of $3,000 per month,which was owed to him and being accrued by the Company in the total amount of $17,048. Then, on March 24, 2023, he converted the amount due to him in 17,048,000 shares of the Company’s common stock. Of the total amount of the $8,048 earned by Mr. Lin through September 30, 2022, as executive compensation, $0 was paid and $8,048 was accrued. Additionally, Mr. Lin served as our President and Chief Executive Officer from August 1, 2021, until October 29, 2021. From August 1, 2021, through September 30, 2021, Mr. Lin received compensation of $2,500 a month. All accrued and unpaid compensation has been converted to shares of our Common Stock.

 

4From September 30, 2021 to September 30, 2022, Mr. Tsai was entitled to receive his compensation in the amount of $1,800 per month. Of the total amount of the $20,755 earned by Mr. Tsai through September 30, 2022, as executive compensation, $0 was paid and $20,755 was accrued. On March 24, 2023, Mr. Tsai converted the accrued amount of his compensation into 26,155,000 shares of the Company Common Stock. From July 22, 2023, Mr. Tsai was appointed as Chief Financial Officer.

 

5From September 30, 2021, through September 30, 2022, Mr. Su was entitled to receive his compensation in the amount of $1,800 per month as the treasurer. Of the total amount of the $17,188.94 earned by Mr. Su through September 30, 2022, $2,200 was paid and $14,988.94 was accrued. Mr. Su has accrued $18,271.12 and converted 18,271,120 into the Company’s Common Stock.

 

6

From September 30, 2021, through September 30, 2022, Ms. Lin was entitled to receive her compensation in the amount of $1,800 per month as the secretary. Of the total amount of the $4,529 earned by Ms. Lin through September 30, 2022, $0 was paid and $4,529 was accrued. Ms. Lin has accrued $9,929 of unpaid compensation , which was converted into 9,929,000 shares of the Company’s Common Stock. Additionally, in fiscal year 2023, Ms. Lin accrued $5,400 in compensation, which was then converted into 9,929,000 shares of the Company’s Common Stock.

 

16

 

 

Employment Agreements

 

We have not entered into employment agreements with any of our named executive officers except for David Tang, CEO and Kuang Ming (James) Tsai, CFO.

 

Employment Contract - David Tang

 

On July 29, 2022, the Company and David Tang (the “Executive”) executed an employment agreement (the “Employment Agreement”) dated July 29, 2022. Pursuant to the Employment Agreement, the Executive’s full time employment with the Company as the Chief Executive Officer began on July 15, 2022, and the Executive’s responsibilities include executing development of electric vehicle supply equipment (“EVSE”) or commonly known as charging stations and coordinating global strategy and marketing. Additionally, under the Employment Agreement, the Executive shall receive an annual base salary of $150,000 and be eligible for annual bonus subject to certain millstones as mutually agreed by the Executive and the board of directors (the “Board”) of the Company. In accordance with the Employment Agreement, the Executive is also eligible for other benefits, such as medical/dental insurance and telecommunication/commuting reimbursements and paid vacation days.

 

In connection with the Employment Agreement, on July 29, 2022, the Company and the Executive entered into a stock option agreement (the “Stock Option Agreement”), pursuant to which the Company granted the Executive the stock option (the “Stock Option”) as of July 15, 2022 (the “Date of Grant”) to purchase 15,000,000 shares of the Company’s common stock with the first twenty-five percent (25%) of the Stock Option to be vested on July 15, 2023; the second twenty-five percent (25%) of the Stock Option to be vested on July 15, 2024; the third twenty-five percent (25%) of the Stock Option to be vested on July 15, 2025; and the fourth twenty-five percent (25%) of the Stock Option to be vested on July 15, 2026. Unless terminated earlier pursuant to the Stock Option Agreement, the Stock Option shall expire on July 15, 2032 (the “Expiration Date”).

 

Employment Contract – Kuang Ming (James) Tsai

 

On July 22, 2023, the Company and Kuang Ming (James) Tsai (the “CFO”) executed an employment agreement (the “CFO Employment Agreement”). Pursuant to the CFO Employment Agreement, Mr. Tsai will be responsible for duties pertaining to the Chief Financial Officer, including financial reporting and fund raising. The Company and Mr. Tsai hereby agree that the Company will pay Mr. Tsai a special one-time bonus upon successful fund raise of the Company as a result of Mr. Tsai’s efforts or relationships, payable upon receipt of such investment. The special one-time bonus will be four percent (4%) of the total proceeds for any new funding up to $250,000.00, and five percent (5%) of the total proceeds for any new funding over $250,000.00.

 

Additionally, as Mr. Tsai is a significant shareholder in the Company, he will forgo any monthly cash compensation, and pursuant to the agreement, the compensation arrangement will be reviewed quarterly, subject to adjustment as needed. Further, Mr. Tsai no longer receives the consultancy compensation as of the start date of the CFO Employment Agreement.

 

Compensation Conversion to Common Stock

 

On December 11, 2022, our Board of Directors authorized that all accrued and unpaid amounts of compensation, as of December 31, 2022, may be converted, at the option of our directors, and present and certain former executive officers, into shares of our Common Stock. No further action has taken place.

 

Outstanding Equity Awards at Fiscal Year-End

 

There are no outstanding equity awards to any of our named executive officers other than the stock option issued to David Tang.

 

No retirement, pension, profit sharing, stock option or insurance programs or other similar programs have been adopted by the Company. We have no present intention of adopting any such plans in the foreseeable future.

 

17

 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth, as of December 31, 2023, the number of shares of our Common Stock owned of record and beneficially by all directors, executive officers and persons who beneficially own more than 5% of the outstanding shares of Common Stock of the Company. We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of Common Stock that they beneficially own.

 

Name and Address  Amount
and Nature of
Beneficial
Ownership
   Percentage
of Class(1)
 
5% or more Stockholders:        
Shao-cheng Wang
No. 11, Ln. 120, Yongshun St.,
Dajia Dist., Taichung City 437
Taiwan 402 (R.O.C)
   87,155,889    10.77%
           
Directors and Executive Officers:          
David Tang
1108 S. Baldwin Avenue, Suite 107
Arcadia, California 91007
   0    0%
Jui Pin (John) Lin
1108 S. Baldwin Avenue, Suite 107
Arcadia, California 91007
   80,468,000(2)   9.95%
Wen-Piao (Jack) Lai
1108 S. Baldwin Avenue, Suite 107
Arcadia, California 91007
   72,070,500    8.91%
Kuang Ming (James) Tsai
1108 S. Baldwin Avenue, Suite 107
Arcadia, California 91007
   31,555,000    3.90%
Hui-Chuan (Sandra) Lin(2)
1108 S. Baldwin Avenue, Suite 107
Arcadia, California 91007
   14,433,400(2)   1.76%
Hsin-Ta (Darren) Su
1108 S. Baldwin Avenue, Suite 107
Arcadia, California 91007
   32,077,196    3.97%
All Directors and Executive Officers as a group (5 persons)   230,395,696    39.2%

 

(1) Percentages are calculated on the basis of 808,900,041 shares of Common Stock outstanding as of December 28, 2023.

(2)Hui-Chuan (Sandra) Lin is Jui Pin (John) Lin’s daughter.

 

18

 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Related Parties

 

Name of related parties   Relationship with the Company
Yi Lung (Oliver) Lin   Principal shareholder
Jui Pin (John) Lin   Principal shareholder, Director, Former President and Chief Executive Officer
Jia Tian (Jeffery) Lin   Former Chief Executive Officer
Wen-Piao (Jack) Lai   Director, Former Chief Executive Officer
Kuang Ming (James) Tsai   Director, Chief Financial Officer
Hsin-Ta (Darren) Su   Director, Treasurer
Hui-Chuan (Sandra) Lin   Director, daughter of Jui Pin (John) Lin
David Tang   Chief Executive Officer

 

Due to Related Parties

 

The Company’s due to related parties balances are as follows:

 

   September 30,
2023
   September 30,
2022
 
Kuang Ming (James) Tsai  $                $20,755 
David Tang   14,023      
Jui Pin (John) Lin        8,048 
Jia Tian (Jeffery) Lin        2,500 
Wen-Piao (Jack) Lai        22,210 
Hsin-Ta (Darren) Su   707    17,189 
Hui-Chuan (Sandra) Lin        4,529 
Total  $14,730   $102,831 

 

The related party balances are unsecured, interest-free and due on demand.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 

 

The following table summarizes the fees charged by KCCW Accounting Corp. (“KCCW”) for the services rendered to the company and its subsidiaries in fiscal years of 2023 and 2022:

 

    Amount Billed and Paid  
Type of Fee   Fiscal Year
2022
    Fiscal Year
2023
 
Audit (1)   $ 37,767     $ 34,365  
Audit related (2)     -       -  
Total   $ 37,767     $ 34,365    

 

(1)

Represents aggregate fees charged by KCCW for audits of consolidated financial statements for fiscal years ended September 30, 2022, and 2023, and quarterly reviews during fiscal year 2022 and 2023, respectively.

 

19

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a) Documents filed as part of this report:

 

1. Financial Statements

 

The consolidated financial statements contained herein are as listed on the “Index to Consolidated Financial Statements” on page F-1 of this report.

 

2. Financial Statement Schedule

 

The consolidated financial statement schedule contained herein is as listed on the “Index to Consolidated Financial Statements” on page F-1 of this report. All other schedules have been omitted because they are not applicable, not required, or the information is included in the consolidated financial statements or notes thereto.

 

3. Exhibits

 

See Exhibit Index.

 

(b) Exhibits:

 

20

 

 

The following exhibits are attached hereto and incorporated herein by reference.

 

Exhibit No.   Description
3.1(1)   Articles of Incorporation of Genufood Energy Enzymes Corp. dated June 21, 2010
3.2(1)   Certificate of Amendment dated December 10, 2010 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.3(1)   Certificate of Amendment dated August 1, 2014 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.4(1)   Certificate of Amendment dated February 24, 2015 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.5(2)   Certificate of Change Pursuant to Nevada Revised Statutes Section 78.209, as filed by Genufood Energy Enzymes Corp. with the Secretary of State of the State of Nevada on June 24, 2020.
3.6(3)   Bylaws of Genufood Energy Enzymes Corp.
4.1(4)   Description of Securities
10.1(5)   Stock Purchase Agreement made and entered into as of November 17, 2021, by and among Genufood Energy Enzymes Corp.; Yu-Lin Chen; and Hukui Biotechnology Corporation
10.2(6)   Agreement dated as of December 17, 2021 by and between Genufood Energy Enzymes Corp. and Hukui Biotechnology Corporation
10.3(7)   Employment Agreement between David Tang and Genufood Energy Enzymes Corp. dated July 29, 2022
10.4(7)   Stock Option Agreement between David Tang and Genufood Energy Enzymes Corp. dated July 29, 2022 

10.5(8)

 

Employment Agreement between Kuang Ming (James) Tsai and Genufood Enzymes Corp. dated July 22, 2023

16.1(9)   Letter from DYH & Company to the Securities and Exchange Commission.
21(4)   List of subsidiaries
23.1*   Consent of Independent Registered Public Accounting Firm KCCW Accountancy Corp.
24.1*   Power of Attorney (included after signatures hereto)
31.1*   Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
31.2*   Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
32.1*   Certification of Periodic Financial Report by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Periodic Financial Report by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.

 

(1) Incorporated by reference from our registration statement on Form 10, filed with the Securities and Exchange Commission on October 25, 2019.
(2) Incorporated by reference from our Current Report on Form 8-K dated June 23, 2020.
(3) Incorporated by reference from our Current Report on Form 8-K dated July 7, 2021.
(4) Incorporated by reference from our Annual Report on Form 10-K dated January 13, 2022
(5) Incorporated by reference from our Current Report on Form 8-K dated November 19, 2021.
(6) Incorporated by reference from our Current Report on Form 8-K dated December 20, 2021.
(7) Incorporated by reference from our Current Report on Form 8-K dated August 4, 2022
(8)

Incorporated by reference from our Current Report on Form 8-K dated July 27, 2023

(9) Incorporated by reference from our Current Report on Form 8-K dated February 28, 2022

 

(c) Financial Statement Schedules:

 

Not applicable

 

ITEM 16. FORM 10-K SUMMARY

 

None.

 

21

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

GENUFOOD ENERGY ENZYMES CORP.

     
Date: January 12, 2024 By: /s/ David Tang
    David Tang
    Chief Executive Officer

 

Signature   Title   Date
     
/s/ David Tang   Chief Executive Officer   January 12, 2024
David Tang   (principal executive officer)    
         
/s/ Jui Pin (John) Lin   Chairman of the Board   January 12, 2024
Jui Pin (John) Lin        
         
/s/ Kuang Ming (James) Tsai   Director and Chief Financial Officer (principal financial officer)   January 12, 2024

Kuang Ming (James) Tsai

 

       
/s/ Wen-Piao (Jack) Lai   Director   January 12, 2024

Wen-Piao (Jack) Lai

 

       
/s/ Hsin-Ta (Darren) Su   Director   January 12, 2024

Hsin-Ta (Darren) Su

 

       
/s/ Hui-Chuan (Sandra) Lin   Director   January 12, 2024

Hui-Chuan (Sandra) Lin

       

 

22

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS  

 

Statement   Page
     
Consolidated Financial Statements for the Years Ended September 30, 2023 and 2022    
     
Index to Consolidated Financial Statements   F-1
     
Report of Independent Registered Public Accounting Firm (PCAOB ID 2851)   F-2
     
Consolidated Balance Sheets as of September 30, 2023 and 2022   F-3
     
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended September 30, 2023 and 2022   F-4
     
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Years Ended September 30, 2023 and 2022   F-5
     
Consolidated Statements of Cash Flows for the Years Ended September 30, 2023 and 2022   F-6
     
Notes to Consolidated Financial Statements   F-7

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

Genufood Energy Enzymes Corporation

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Genufood Energy Enzymes Corporation (the “Company”) as of September 30, 2023, and 2022, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity (deficit), and cash flows for the years then ended and the related notes (collectively referred to as “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2023 and 2022 and the results of its operations and its cash flows for the years ended September 30, 2023 and 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, as of September 30, 2023, the Company had recurring losses from operations, an accumulated deficit, and a negative cash flows from operating activities. As such there is substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

/s/ KCCW Accountancy Corp.

 

We have served as the Company’s auditor since 2022.

Diamond Bar, California

January 11, 2024

 

F-2

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONSOLIDATED BALANCE SHEETS

 

   September 30,   September 30, 
   2023   2022 
       (Restated) 
Assets        
Current assets        
Cash and cash equivalents  $125,924   $136,400 
Prepayment   8,187    14,493 
Total Current Assets   134,111    150,893 
           
Equipment   67,451    
-
 
           
Total Assets  $201,562   $150,893 
           
Liabilities and Stockholders’ Equity          
Current liabilities          
Accounts payable  $100,849   $102,185 
Accrued expenses   37    
-
 
Due to related parties   14,730    102,831 
Total Current Liabilities   115,616    205,016 
           
Commitment and contingencies (Note 9)   32,226    29,226 
           
Stockholders’ Equity (Deficit)          
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of  September 30, 2023 and September 30, 2022, respectively   808,900    299,687 
Additional paid-in capital   16,989,592    16,927,592 
Discount on common stock   (7,241,581)   (7,241,581)
Accumulated deficit   (10,503,191)   (9,875,489)
Accumulated other comprehensive loss   
-
    (193,558)
Total Stockholders’ Equity (Deficit)   53,720    (83,349)
           
Total Liabilities and Stockholders’ Equity  $201,562   $150,893 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

   For the Year Ended
September 30,
 
   2023   2022 
       (Restated) 
Revenue  $
-
   $
-
 
           
Operating expenses          
General and administrative expenses   432,296    348,845 
Total operating expenses   432,296    348,845 
           
Loss from operations   (432,296)   (348,845)
           
Other income (expense)          
Interest income (expense)   2    6 
Loss on disposal of subsidiary   (192,365)   
-
 
Foreign currency income (loss)   (43)   6 
Other non-operating income (expenses), net   (3,000)   (3,835)
Total other expense, net   (195,406)   (3,823)
           
Loss before income taxes   (627,702)   (352,668)
           
Provision for income taxes   
-
    
-
 
           
Net loss   (627,702)   (352,668)
           
Other comprehensive income (loss)          
Foreign currency transaction adjustments   193,558    25 
           
Comprehensive loss  $(434,144)  $(352,643)
           
Loss per share of common stock - basic and diluted    *      *  
           
Weighted average shares outstanding - basic and diluted
   526,044,946    299,686,921 

 

*Less than $0.01 per share

 

The accompanying notes are an integral part of these consolidated financial statements. 

 

F-4

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONSOILDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

 

                     Accumulated   Total 
   Common Stock   Additional   Discount on       Other   Stockholder’s 
   Number of Shares   Amount   Paid-in-
Capital
   common
stock
   Accumulated
Deficit
   Comprehensive
Income (loss)
   Equity
(Deficit)
 
Balance at September 30, 2021   299,686,921   $299,687   $16,911,770   $(7,241,581)  $(9,522,821)  $(193,583)  $253,472 
Stock-based compensation (restated)   -    
-
    15,822    
-
    
-
    
-
    15,822 
Net loss (restated)   -    
-
    
-
    
-
    (352,668)   
-
    (352,668)
Foreign currency translation   -    
-
    
-
    
-
    
-
    25    25 
Balance at September 30, 2022 (restated)   299,686,921    299,687    16,927,592    (7,241,581)   (9,875,489)   (193,558)   (83,349)
Stock-based compensation   -    
-
    75,000    
-
    
-
    
-
    75,000 
Common stock issued   375,000,000    375,000    (13,000)   
-
    
-
    
-
    362,000 
Issuance of common stock for debt conversion   134,213,120    134,213    
-
    
-
    
-
    
-
    134,213 
Disposal of subsidiary   -    
-
    
-
    
-
    
-
    193,643    193,643 
Net loss   -    
-
    
-
    
-
    (627,702)   
-
    (627,702)
Foreign currency translation   -    
-
    
-
    
-
    
-
    (85)   (85)
Balance at September 30, 2023   808,900,041   $808,900   $16,989,592   $(7,241,581)  $(10,503,191)  $
-
   $53,720 

 

The accompanying notes are an integral part of these consolidated financial statements. 

 

F-5

 

 

GENUFOOD ENERGY ENZYMES CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   For the Year Ended
September 30,
 
   2023   2022 
       (Restated) 
Cash Flows from Operating Activities        
Net loss   $(627,702)  $(352,668)
Adjustments to reconcile net loss to net cash used in operating activities          
Stock-based compensation    75,000    15,822 
Loss on disposal of subsidiary    192,365    
-
 
Change in operating assets and liabilities           
Prepayment    6,306    11,280 
Accounts payable    (143)   1,507 
Accrued expenses    37    (1,590)
Due to related parties    46,112    99,821 
Commitment and contingencies    3,000    3,000 
Net cash used in operating activities    (305,025)   (222,828)
           
Cash Flows from Investing Activities           
Purchase of equipment    (67,451)   
-
 
Proceeds from sale of Hukui investment    
-
    350,000 
Net cash (used in) provided by investing activities   (67,451)   350,000 
           
Cash Flows from Financing Activities           
Proceeds from issuance of common stock, net of offering costs   362,000    
-
 
Net cash provided by financing activities    362,000    
-
 
           
Effect of exchange rate changes on cash and cash equivalents   
-
    (43)
           
Net (decrease) increase in cash and cash equivalents   (10,476)   127,129 
           
Cash and cash equivalents, beginning of period   136,400    9,271 
Cash and cash equivalents, end of period   $125,924   $136,400 
           
Supplemental Disclosures           
Cash paid for interest   $
-
   $
-
 
Cash paid for income taxes   $
-
   $
-
 
           
Supplemental Non-Cash Investing and Financing Activities          
Issuance of common stock for debt conversion   $134,213   $
-
 

  

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6

 

 

GENUFOOD ENERGY ENZYMES CORP

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL ORGANIZATION AND BUSINESS

 

Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which was dissolved on January 9, 2023.

 

Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the year ended September 30, 2023, the Company has initiated its electric vehicle charging station business.

 

The Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

 

On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

 

On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.

 

As of September 30, 2023, the Company has two sites under construction for charging stations and three sites under planning.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

 

Principle of Consolidation

 

The consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

F-7

 

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of September 30, 2023, and 2022, the Company did not have cash equivalents.

 

Fair Value of Financial Instruments

 

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

  Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.
     
  Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.
     
  Level 3 inputs are less observable and reflect our own assumptions.

 

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

 

Foreign Currency Translation and Transactions

 

The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

 

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7293 average exchange rates were used to translate revenues and expenses for the year ended September 30, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying consolidated statements of operations.

 

Business Segments

 

The Company operates in only one segment.

 

Net Income (Loss) Per Share

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the years ended September 30, 2023 and 2022.

 

F-8

 

 

Discounts on Common Stock

 

Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s consolidated financial statements.

 

Stock-Based Compensation

 

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

 

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

 

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

 

There were no current and deferred income tax provision recorded for the years ended September 30, 2023 and 2022 since the Company has recurring losses.

 

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

 

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

 

F-9

 

 

NOTE 3 – GOING CONCERN

 

As of September 30, 2023, and 2022, the Company had an accumulated deficit of $10,503,191 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

 

The Company sold the 140,000 Hukui Shares for $350,000 in cash on November 19, 2021, and received $362,000 from private placement during the year ended September 30, 2023. The proceeds have been used for operation expenses. Management is currently seeking additional funds for future operation.

 

NOTE 4 – EQUIPMENT

 

As of September 30, 2023, and 2022 the Company had equipment of $67,451 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations and related installation costs.

 

NOTE 5 – INVESTMENT

 

Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment was recorded at cost.

 

On November 17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.

 

NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

 

On February 24, 2023, the Company conducted a private placement offering and sold 375,000,000 shares of common stock at $0.001 per share, for gross proceeds of $375,000, and incurred offering costs of $13,000.

 

On March 24, 2023, the Company issued 134,213,120 shares of common stock to its board of directors, officers, and former officers to repay the compensation due to them in the aggregate amount of $134,213 at the conversion rate of $0.001 per share.

 

F-10

 

 

Stock Options

 

On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of September 30, 2023, total options granted was 15,000,000 and 4,375,000 was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.

 

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $75,000 and $15,822, respectively, which was included in the general and administrative expenses in the consolidated statements of operations for the years ended September 30, 2023 and 2022.

 

The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:

 

   September 30,
2023
 
Risk-free interest rate   2.99%
Expected term   6.08 years 
Expected volatility   379.35%
Expected dividend yield   0%

 

The following is a summary of the option activity for the year ended September 30, 2023:

 

Options  Number of
Underlying
Shares
   Weighted
average
exercise
price
   Weighted
Average
Remaining
Contractual
Life (years)
   Aggregate
Intrinsic
Value
 
Outstanding at October 1, 2022   15,000,000   $0.01    
   $
           –
 
Granted   
   $
       $ 
Exercised   
   $
       $ 
Forfeited or expired   
   $
       $ 
Outstanding at September 30, 2023   15,000,000   $0.01    8.8   $
 
Vested and expected to vest as of September 30, 2023   15,000,000   $0.01    8.8   $
 
Exercisable at September 30, 2023   4,375,000   $0.01    8.8   $
 

 

As of September 30, 2023, unrecognized total compensation cost associated with these options was $209,178. This expense is expected to be recognized over a weighted-average period of 2.79 years.

 

F-11

 

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Related Parties

 

Name of related parties   Relationship with the Company
Yi Lung (Oliver) Lin   Principal shareholder
Jui Pin (John) Lin   Principal shareholder, Chairman of the Board, President, and Director
Jia Tian (Jeffery) Lin   Former Chief Executive Officer
Wen-Piao (Jack) Lai   Director
Shao-Cheng (Will) Wang   Former Chief Financial Officer
Kuang Ming (James) Tsai   Director and Chief Financial Officer
Hsin-Ta (Darren) Su   Director, Treasurer
Hui-Chuan (Sandra) Lin   Director and Secretary, daughter of Jui Pin (John) Lin
David Tang   Chief Executive Officer

 

Due to Related Parties

 

The Company’s due to related parties balances are as follows:

 

   September 30,
2023
   September 30,
2022
 
Kuang Ming (James) Tsai  $
-
   $20,755 
Jui Pin (John) Lin   
-
    8,048 
Jia Tian (Jeffery) Lin   
-
    2,500 
Shao-Cheng (Will) Wang   
-
    27,600 
Wen-Piao (Jack) Lai   
-
    22,210 
Hsin-Ta (Darren) Su   707    17,189 
Hui-Chuan (Sandra) Lin   
-
    4,529 
David Tang   14,023    
-
 
Total  $14,730   $102,831 

 

The related party balances are unsecured, interest-free and due on demand.

 

NOTE 8 – INCOME TAXES

 

The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.

 

F-12

 

 

Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

 

The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $7,226, for a total of $32,226, which was still pending as of September 30, 2023.

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

The Company terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of September 30, 2023, the Company has no material commitments under operating leases.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 8).

 

NOTE 10 – SUBSEQUENT EVENTS

 

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.

 

 

F-13

 

 

299686921 526044946 false FY 0001510518 0 0001510518 2022-10-01 2023-09-30 0001510518 2024-01-09 0001510518 2023-03-31 0001510518 2023-09-30 0001510518 2022-09-30 0001510518 us-gaap:RelatedPartyMember 2023-09-30 0001510518 us-gaap:RelatedPartyMember 2022-09-30 0001510518 2021-10-01 2022-09-30 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-10-01 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-10-01 2023-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2023-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2023-09-30 0001510518 us-gaap:CommonStockMember 2023-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2023-09-30 0001510518 us-gaap:RetainedEarningsMember 2023-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-11-17 2021-11-17 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 gfoo:HukuiSharesMember 2021-11-19 0001510518 gfoo:HukuiSharesMember 2021-11-01 2021-11-19 0001510518 gfoo:HukuiSharesMember 2022-10-01 2023-09-30 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-19 2021-11-19 0001510518 2023-02-24 0001510518 2023-02-24 2023-02-24 0001510518 2023-03-24 0001510518 2023-03-24 2023-03-24 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-09-30 0001510518 us-gaap:StockOptionMember gfoo:VestingMember 2022-10-01 2023-09-30 0001510518 gfoo:VestingMember 2022-10-01 2023-09-30 0001510518 us-gaap:StockOptionMember 2022-10-01 2023-09-30 0001510518 us-gaap:StockOptionMember 2021-10-01 2022-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2023-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2023-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2023-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2023-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2023-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2023-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2023-09-30 0001510518 gfoo:DavidTangMember 2022-10-01 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2023-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2023-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2023-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2023-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2023-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2023-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:DavidTangMember 2023-09-30 0001510518 gfoo:DavidTangMember 2022-09-30 0001510518 us-gaap:RelatedPartyMember 2023-09-30 0001510518 us-gaap:RelatedPartyMember 2022-09-30 0001510518 2019-10-01 2020-09-30 0001510518 2020-10-01 2021-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares gfoo:Segment xbrli:pure
EX-23.1 2 f10k2023ex23-1genufood.htm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRN DYH & COMPANY

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the inclusion in this Annual Report on Form 10-K, as amended, of Genufood Energy Enzymes Corp. (the “Company”) for the years ended September 30, 2022 and 2023, of our report dated January 12, included in its Form 10-K, as amended, with respect to our audits of the consolidated financial statements of the Company as of September 30, 2023, and for the year ended September 30, 2023.

 

/s/ KCCW Accountancy Corp.  
Diamond Bar, California  
January 12, 2024  

 

 

EX-31.1 3 f10k2023ex31-1_genufood.htm CERTIFICATION

Exhibit 31.1

 

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934

 

I, David Tang, certify that:

 

1.I have reviewed this Annual Report on Form 10-K of Genufood Energy Enzymes Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 12, 2024 /s/ David Tang
  David Tang
  Chief / Principal Executive Officer

 

 

EX-31.2 4 f10k2023ex31-2_genufood.htm CERTIFICATION

Exhibit 31.2

 

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934

 

I, Kuang Ming (James) Tsai, certify that:

 

1.I have reviewed this Annual Report on Form 10-K of Genufood Energy Enzymes Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 12, 2024 /s/ KUANG MING (JAMES) TSAI
  Kuang Ming (James) Tsai
  Chief / Principal Financial Officer

 

 

EX-32 5 f10k2023ex32-1_genufood.htm CERTIFICATION

Exhibit 32.1

 

Certification of Periodic Financial Report by the Chief Executive Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Solely for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, the undersigned Chief Executive Officer of Genufood Energy Enzymes Corp. (the “Company”), hereby certify, based on my knowledge, that the Annual Report on Form 10-K of the Company for the year ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: January 12, 2024 /s/ David Tang
  David Tang
  Chief Executive Officer
(principal executive officer)

 

EX-32.2 6 f10k2023ex32-2_genufood.htm CERTIFICATION

Exhibit 32.2

 

Certification of Periodic Financial Report by the Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Solely for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, the undersigned Chief Financial Officer of Genufood Energy Enzymes Corp. (the “Company”), hereby certify, based on my knowledge, that the Annual Report on Form 10-K of the Company for the year ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: January 12, 2024 /s/ Kuang Ming (James) Tsai
  Kuang Ming (James) Tsai
  Chief Financial Officer
(principal accounting officer)

 

 

EX-101.SCH 7 gfoo-20230930.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consoildated Statements of Stockholders’ Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - General Organization and Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Equipment link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Investment link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stockholders’ Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Stockholders’ Equity (Deficit) (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - General Organization and Business (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Investment (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Stockholders’ Equity (Deficit) (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Stockholders’ Equity (Deficit) (Details) - Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Stockholders’ Equity (Deficit) (Details) - Schedule of Option Activity link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Related Party Transactions (Details) - Schedule of Related Parties Name and Relationship link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Related Party Transactions (Details) - Schedule of Due to Related Parties Balances link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 gfoo-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 gfoo-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 gfoo-20230930_lab.xml XBRL LABEL FILE EX-101.PRE 11 gfoo-20230930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information - USD ($)
12 Months Ended
Sep. 30, 2023
Jan. 09, 2024
Mar. 31, 2023
Document Information Line Items      
Entity Registrant Name GENUFOOD ENERGY ENZYMES CORP.    
Document Type 10-K    
Current Fiscal Year End Date --09-30    
Entity Common Stock, Shares Outstanding   808,900,041  
Entity Public Float     $ 0
Amendment Flag false    
Entity Central Index Key 0001510518    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Document Period End Date Sep. 30, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
ICFR Auditor Attestation Flag false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 000-56112    
Entity Incorporation, State or Country Code NV    
Entity Tax Identification Number 68-0681158    
Entity Address, Address Line One 1108 S. Baldwin Avenue    
Entity Address, Address Line Two Suite 107    
Entity Address, City or Town Arcadia    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91007    
City Area Code (855)    
Local Phone Number 707-2077    
Entity Interactive Data Current Yes    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 2851    
Auditor Name KCCW Accountancy Corp.    
Auditor Location California    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Sep. 30, 2022
Current assets    
Cash and cash equivalents $ 125,924 $ 136,400
Prepayment 8,187 14,493
Total Current Assets 134,111 150,893
Equipment 67,451
Total Assets 201,562 150,893
Current liabilities    
Accounts payable 100,849 102,185
Accrued expenses 37
Total Current Liabilities 115,616 205,016
Commitment and contingencies (Note 9) 32,226 29,226
Stockholders’ Equity (Deficit)    
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of September 30, 2023 and September 30, 2022, respectively 808,900 299,687
Additional paid-in capital 16,989,592 16,927,592
Discount on common stock (7,241,581) (7,241,581)
Accumulated deficit (10,503,191) (9,875,489)
Accumulated other comprehensive loss (193,558)
Total Stockholders’ Equity (Deficit) 53,720 (83,349)
Total Liabilities and Stockholders’ Equity 201,562 150,893
Related Party    
Current liabilities    
Due to related parties $ 14,730 $ 102,831
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Balance Sheets (Parentheticals) - $ / shares
Sep. 30, 2023
Sep. 30, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 10,000,000,000 10,000,000,000
Common stock, shares issued 808,900,041 299,686,921
Common stock, shares outstanding 808,900,041 299,686,921
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue
Operating expenses    
General and administrative expenses 432,296 348,845
Total operating expenses 432,296 348,845
Loss from operations (432,296) (348,845)
Other income (expense)    
Interest income (expense) 2 6
Loss on disposal of subsidiary (192,365)
Foreign currency income (loss) (43) 6
Other non-operating income (expenses), net (3,000) (3,835)
Total other expense, net (195,406) (3,823)
Loss before income taxes (627,702) (352,668)
Provision for income taxes
Net loss (627,702) (352,668)
Other comprehensive income (loss)    
Foreign currency transaction adjustments 193,558 25
Comprehensive loss $ (434,144) $ (352,643)
Loss per share of common stock - basic (in Dollars per share) [1]
Weighted average shares outstanding - basic (in Shares) 526,044,946 299,686,921
[1] Less than $0.01 per share
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares
12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Loss per share of common stock diluted [1]
Weighted average shares outstanding diluted (in Shares) 526,044,946 299,686,921
[1] Less than $0.01 per share
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.4
Consoildated Statements of Stockholders’ Equity (Deficit) - USD ($)
Common Stock
Additional Paid-in- Capital
Discount on common stock
Accumulated Deficit
Accumulated Other Comprehensive Income (loss)
Total
Balance at Sep. 30, 2021 $ 299,687 $ 16,911,770 $ (7,241,581) $ (9,522,821) $ (193,583) $ 253,472
Balance (in Shares) at Sep. 30, 2021 299,686,921          
Stock-based compensation 15,822 15,822
Net loss (352,668) (352,668)
Foreign currency translation 25 25
Balance at Sep. 30, 2022 $ 299,687 16,927,592 (7,241,581) (9,875,489) (193,558) $ (83,349)
Balance (in Shares) at Sep. 30, 2022 299,686,921         299,686,921
Stock-based compensation 75,000 $ 75,000
Common stock issued $ 375,000 (13,000) 362,000
Common stock issued (in Shares) 375,000,000          
Issuance of common stock for debt conversion $ 134,213 134,213
Issuance of common stock for debt conversion (in Shares) 134,213,120          
Disposal of subsidiary 193,643 193,643
Net loss (627,702) (627,702)
Foreign currency translation (85) (85)
Balance at Sep. 30, 2023 $ 808,900 $ 16,989,592 $ (7,241,581) $ (10,503,191) $ 53,720
Balance (in Shares) at Sep. 30, 2023 808,900,041         808,900,041
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows from Operating Activities    
Net loss $ (627,702) $ (352,668)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 75,000 15,822
Loss on disposal of subsidiary 192,365
Change in operating assets and liabilities    
Prepayment 6,306 11,280
Accounts payable (143) 1,507
Accrued expenses 37 (1,590)
Due to related parties 46,112 99,821
Commitment and contingencies 3,000 3,000
Net cash used in operating activities (305,025) (222,828)
Cash Flows from Investing Activities    
Purchase of equipment (67,451)
Proceeds from sale of Hukui investment 350,000
Net cash (used in) provided by investing activities (67,451) 350,000
Cash Flows from Financing Activities    
Proceeds from issuance of common stock, net of offering costs 362,000
Net cash provided by financing activities 362,000
Effect of exchange rate changes on cash and cash equivalents (43)
Net (decrease) increase in cash and cash equivalents (10,476) 127,129
Cash and cash equivalents, beginning of period 136,400 9,271
Cash and cash equivalents, end of period 125,924 136,400
Supplemental Disclosures    
Cash paid for interest
Cash paid for income taxes
Supplemental Non-Cash Investing and Financing Activities    
Issuance of common stock for debt conversion $ 134,213
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.4
General Organization and Business
12 Months Ended
Sep. 30, 2023
General Organization and Business [Abstract]  
GENERAL ORGANIZATION AND BUSINESS

NOTE 1 – GENERAL ORGANIZATION AND BUSINESS

 

Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which was dissolved on January 9, 2023.

 

Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the year ended September 30, 2023, the Company has initiated its electric vehicle charging station business.

 

The Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

 

On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

 

On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.

 

As of September 30, 2023, the Company has two sites under construction for charging stations and three sites under planning.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.4
Summary of Significant Accounting Policies
12 Months Ended
Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

 

Principle of Consolidation

 

The consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of September 30, 2023, and 2022, the Company did not have cash equivalents.

 

Fair Value of Financial Instruments

 

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

 

  Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.
     
  Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.
     
  Level 3 inputs are less observable and reflect our own assumptions.

 

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

 

Foreign Currency Translation and Transactions

 

The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

 

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7293 average exchange rates were used to translate revenues and expenses for the year ended September 30, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying consolidated statements of operations.

 

Business Segments

 

The Company operates in only one segment.

 

Net Income (Loss) Per Share

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the years ended September 30, 2023 and 2022.

 

Discounts on Common Stock

 

Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s consolidated financial statements.

 

Stock-Based Compensation

 

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

 

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

 

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

 

There were no current and deferred income tax provision recorded for the years ended September 30, 2023 and 2022 since the Company has recurring losses.

 

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

 

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.4
Going Concern
12 Months Ended
Sep. 30, 2023
Going Concern [Abstract]  
GOING CONCERN

NOTE 3 – GOING CONCERN

 

As of September 30, 2023, and 2022, the Company had an accumulated deficit of $10,503,191 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

 

The Company sold the 140,000 Hukui Shares for $350,000 in cash on November 19, 2021, and received $362,000 from private placement during the year ended September 30, 2023. The proceeds have been used for operation expenses. Management is currently seeking additional funds for future operation.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.4
Equipment
12 Months Ended
Sep. 30, 2023
Equipment [Abstract]  
EQUIPMENT

NOTE 4 – EQUIPMENT

 

As of September 30, 2023, and 2022 the Company had equipment of $67,451 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations and related installation costs.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.4
Investment
12 Months Ended
Sep. 30, 2023
Investment [Abstract]  
INVESTMENT

NOTE 5 – INVESTMENT

 

Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment was recorded at cost.

 

On November 17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Equity (Deficit)
12 Months Ended
Sep. 30, 2023
Stockholders’ Equity (Deficit) [Abstract]  
STOCKHOLDERS’ EQUITY (DEFICIT)

NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

 

On February 24, 2023, the Company conducted a private placement offering and sold 375,000,000 shares of common stock at $0.001 per share, for gross proceeds of $375,000, and incurred offering costs of $13,000.

 

On March 24, 2023, the Company issued 134,213,120 shares of common stock to its board of directors, officers, and former officers to repay the compensation due to them in the aggregate amount of $134,213 at the conversion rate of $0.001 per share.

 

Stock Options

 

On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of September 30, 2023, total options granted was 15,000,000 and 4,375,000 was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.

 

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $75,000 and $15,822, respectively, which was included in the general and administrative expenses in the consolidated statements of operations for the years ended September 30, 2023 and 2022.

 

The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:

 

   September 30,
2023
 
Risk-free interest rate   2.99%
Expected term   6.08 years 
Expected volatility   379.35%
Expected dividend yield   0%

 

The following is a summary of the option activity for the year ended September 30, 2023:

 

Options  Number of
Underlying
Shares
   Weighted
average
exercise
price
   Weighted
Average
Remaining
Contractual
Life (years)
   Aggregate
Intrinsic
Value
 
Outstanding at October 1, 2022   15,000,000   $0.01    
   $
           –
 
Granted   
   $
       $ 
Exercised   
   $
       $ 
Forfeited or expired   
   $
       $ 
Outstanding at September 30, 2023   15,000,000   $0.01    8.8   $
 
Vested and expected to vest as of September 30, 2023   15,000,000   $0.01    8.8   $
 
Exercisable at September 30, 2023   4,375,000   $0.01    8.8   $
 

 

As of September 30, 2023, unrecognized total compensation cost associated with these options was $209,178. This expense is expected to be recognized over a weighted-average period of 2.79 years.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions
12 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Related Parties

 

Name of related parties   Relationship with the Company
Yi Lung (Oliver) Lin   Principal shareholder
Jui Pin (John) Lin   Principal shareholder, Chairman of the Board, President, and Director
Jia Tian (Jeffery) Lin   Former Chief Executive Officer
Wen-Piao (Jack) Lai   Director
Shao-Cheng (Will) Wang   Former Chief Financial Officer
Kuang Ming (James) Tsai   Director and Chief Financial Officer
Hsin-Ta (Darren) Su   Director, Treasurer
Hui-Chuan (Sandra) Lin   Director and Secretary, daughter of Jui Pin (John) Lin
David Tang   Chief Executive Officer

 

Due to Related Parties

 

The Company’s due to related parties balances are as follows:

 

   September 30,
2023
   September 30,
2022
 
Kuang Ming (James) Tsai  $
-
   $20,755 
Jui Pin (John) Lin   
-
    8,048 
Jia Tian (Jeffery) Lin   
-
    2,500 
Shao-Cheng (Will) Wang   
-
    27,600 
Wen-Piao (Jack) Lai   
-
    22,210 
Hsin-Ta (Darren) Su   707    17,189 
Hui-Chuan (Sandra) Lin   
-
    4,529 
David Tang   14,023    
-
 
Total  $14,730   $102,831 

 

The related party balances are unsecured, interest-free and due on demand.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes
12 Months Ended
Sep. 30, 2023
Income Taxes [Abstract]  
INCOME TAXES

NOTE 8 – INCOME TAXES

 

The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.

 

Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

 

The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $7,226, for a total of $32,226, which was still pending as of September 30, 2023.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.4
Commitments and Contingencies
12 Months Ended
Sep. 30, 2023
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

The Company terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of September 30, 2023, the Company has no material commitments under operating leases.

 

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 8).

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.4
Subsequent Events
12 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

 

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.4
Accounting Policies, by Policy (Policies)
12 Months Ended
Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

Principle of Consolidation

Principle of Consolidation

The consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Concentrations of Credit Risk

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of September 30, 2023, and 2022, the Company did not have cash equivalents.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

  Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.
     
  Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.
     
  Level 3 inputs are less observable and reflect our own assumptions.

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

Foreign Currency Translation and Transactions

Foreign Currency Translation and Transactions

The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7293 average exchange rates were used to translate revenues and expenses for the year ended September 30, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying consolidated statements of operations.

Business Segments

Business Segments

The Company operates in only one segment.

Net Income (Loss) Per Share

Net Income (Loss) Per Share

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the years ended September 30, 2023 and 2022.

 

Discounts on Common Stock

Discounts on Common Stock

Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s consolidated financial statements.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

Income Taxes

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

There were no current and deferred income tax provision recorded for the years ended September 30, 2023 and 2022 since the Company has recurring losses.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Equity (Deficit) (Tables)
12 Months Ended
Sep. 30, 2023
Stockholders’ Equity (Deficit) [Abstract]  
Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:
   September 30,
2023
 
Risk-free interest rate   2.99%
Expected term   6.08 years 
Expected volatility   379.35%
Expected dividend yield   0%
Schedule of Option Activity The following is a summary of the option activity for the year ended September 30, 2023:
Options  Number of
Underlying
Shares
   Weighted
average
exercise
price
   Weighted
Average
Remaining
Contractual
Life (years)
   Aggregate
Intrinsic
Value
 
Outstanding at October 1, 2022   15,000,000   $0.01    
   $
           –
 
Granted   
   $
       $ 
Exercised   
   $
       $ 
Forfeited or expired   
   $
       $ 
Outstanding at September 30, 2023   15,000,000   $0.01    8.8   $
 
Vested and expected to vest as of September 30, 2023   15,000,000   $0.01    8.8   $
 
Exercisable at September 30, 2023   4,375,000   $0.01    8.8   $
 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions (Tables)
12 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Schedule of Related Parties Name and Relationship
Name of related parties   Relationship with the Company
Yi Lung (Oliver) Lin   Principal shareholder
Jui Pin (John) Lin   Principal shareholder, Chairman of the Board, President, and Director
Jia Tian (Jeffery) Lin   Former Chief Executive Officer
Wen-Piao (Jack) Lai   Director
Shao-Cheng (Will) Wang   Former Chief Financial Officer
Kuang Ming (James) Tsai   Director and Chief Financial Officer
Hsin-Ta (Darren) Su   Director, Treasurer
Hui-Chuan (Sandra) Lin   Director and Secretary, daughter of Jui Pin (John) Lin
David Tang   Chief Executive Officer
Schedule of Due to Related Parties Balances The Company’s due to related parties balances are as follows:
   September 30,
2023
   September 30,
2022
 
Kuang Ming (James) Tsai  $
-
   $20,755 
Jui Pin (John) Lin   
-
    8,048 
Jia Tian (Jeffery) Lin   
-
    2,500 
Shao-Cheng (Will) Wang   
-
    27,600 
Wen-Piao (Jack) Lai   
-
    22,210 
Hsin-Ta (Darren) Su   707    17,189 
Hui-Chuan (Sandra) Lin   
-
    4,529 
David Tang   14,023    
-
 
Total  $14,730   $102,831 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.4
General Organization and Business (Details) - Series C Preferred Stock [Member] - Hukui Biotechnology Corporation (“Hukui”) [Member] - USD ($)
Nov. 17, 2021
Jun. 25, 2021
Dec. 15, 2020
General Organization and Business [Line Items]      
Purchase of shares   60,000 80,000
Amount of shares purchased   $ 600,000 $ 800,000
Sale of shares 140,000    
Cash consideration $ 350,000    
Price per share $ 2.5    
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.4
Summary of Significant Accounting Policies (Details)
12 Months Ended
Sep. 30, 2023
Segment
Sep. 30, 2022
$ / shares
Summary of Significant Accounting Policies [Abstract]    
Exchange rate   $ 0.697
Average exchange rates   $ 0.7293
Number of segments (in Segment) | Segment 1  
Tax benefit, percentage 50.00%  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.4
Going Concern (Details) - USD ($)
1 Months Ended 12 Months Ended
Nov. 19, 2021
Sep. 30, 2023
Sep. 30, 2022
Going Concern (Details) [Line Items]      
Accumulated deficit   $ (10,503,191) $ (9,875,489)
Hukui Shares [Member]      
Going Concern (Details) [Line Items]      
Company sold shares (in Shares) 140,000    
Proceeds from sale of Hukui investment $ 350,000    
Private placement   $ 362,000  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.4
Equipment (Details) - USD ($)
Sep. 30, 2023
Sep. 30, 2022
Equipment [Abstract]    
Equipment $ 67,451 $ 0
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.4
Investment (Details) - USD ($)
1 Months Ended 12 Months Ended
Nov. 19, 2021
Dec. 15, 2020
Nov. 17, 2021
Jun. 25, 2021
Sep. 23, 2020
Sep. 30, 2023
Mar. 24, 2023
Sep. 30, 2021
Investment (Details) [Line Items]                
Share price (in Dollars per share)             $ 0.001  
Total investment           $ 1,400,000    
Percentage of equity investment           20.00%    
Loss on sale $ 1,050,000              
Loss of market value               $ 1,050,000
Series C Preferred Shares [Member]                
Investment (Details) [Line Items]                
Share price (in Dollars per share)   $ 10   $ 10        
Purchase shares of stock (in Shares)   80,000            
Purchase price   $ 800,000   $ 600,000        
Purchase of additional shares (in Shares)       60,000        
Hukui Agreement [Member] | Series C Preferred Shares [Member]                
Investment (Details) [Line Items]                
Purchase aggregate shares (in Shares)         200,000      
Share price (in Dollars per share)     $ 2.5   $ 10      
Aggregate investment         $ 2,000,000      
Selling aggregate shares (in Shares)     140,000          
Selling shares value     $ 350,000          
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Equity (Deficit) (Details) - USD ($)
12 Months Ended
Mar. 24, 2023
Feb. 24, 2023
Jul. 15, 2022
Sep. 30, 2023
Sep. 30, 2022
Stockholders’ Equity (Deficit) [Line Items]          
Common stock, shares authorized 134,213,120 375,000,000   10,000,000,000 10,000,000,000
Common stock, par value   $ 0.001   $ 0.001 $ 0.001
Gross proceeds   $ 375,000   $ 362,000
Offering costs   $ 13,000      
Aggregate amount $ 134,213        
Conversion per share $ 0.001        
Options to purchase share       4,375,000  
Stock based compensation expense       $ 75,000 $ 15,822
Compensation cost       $ 209,178  
Stock option period       2 years 9 months 14 days  
Stock Options [Member]          
Stockholders’ Equity (Deficit) [Line Items]          
Stock option period       10  
Stock price         $ 0.02
Share-Based Payment Arrangement, Tranche One [Member]          
Stockholders’ Equity (Deficit) [Line Items]          
Options to purchase share       15,000,000  
Vesting [Member]          
Stockholders’ Equity (Deficit) [Line Items]          
Vesting right percentage       75.00%  
Vesting [Member] | Stock Options [Member]          
Stockholders’ Equity (Deficit) [Line Items]          
Vesting right percentage       25.00%  
Chief Executive Officer [Member]          
Stockholders’ Equity (Deficit) [Line Items]          
Granted options     15,000,000    
Options per share     $ 0.01    
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Equity (Deficit) (Details) - Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model
12 Months Ended
Sep. 30, 2023
Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model [Abstract]  
Risk-free interest rate 2.99%
Expected term 6 years 29 days
Expected volatility 379.35%
Expected dividend yield 0.00%
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ Equity (Deficit) (Details) - Schedule of Option Activity
12 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Schedule of the Option Activity [Abstract]  
Number of Underlying Shares, Beginning Outstanding | shares 15,000,000
Weighted average exercise price, Beginning Outstanding | $ / shares $ 0.01
Weighted Average Remaining Contractual Life (years), Beginning Outstanding
Aggregate Intrinsic Value, Beginning Outstanding | $
Number of Underlying Shares, Granted | shares
Weighted average exercise price, Granted | $ / shares
Number of Underlying Shares, Exercised | shares
Weighted average exercise price, Exercised | $ / shares
Number of Underlying Shares, Forfeited or expired | shares
Weighted average exercise price, Forfeited or expired | $ / shares
Number of Underlying Shares, Ending Outstanding | shares 15,000,000
Weighted average exercise price, Ending Outstanding | $ / shares $ 0.01
Weighted Average Remaining Contractual Life (years), Ending Outstanding 8 years 9 months 18 days
Aggregate Intrinsic Value, Ending Outstanding | $
Number of Underlying Shares Vested and expected to vest | shares 15,000,000
Weighted average exercise price Vested and expected to vest | $ / shares $ 0.01
Weighted Average Remaining Contractual Life (years) Vested and expected to vest 8 years 9 months 18 days
Aggregate Intrinsic Value Vested and expected to vest | $
Number of Underlying Shares, Exercisable | shares 4,375,000
Weighted average exercise price, Exercisable | $ / shares $ 0.01
Weighted Average Remaining Contractual Life (years), Exercisable 8 years 9 months 18 days
Aggregate Intrinsic Value, Exercisable | $
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions (Details) - Schedule of Related Parties Name and Relationship
12 Months Ended
Sep. 30, 2023
Yi Lung (Oliver) Lin [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Principal shareholder
Jui Pin (John) Lin [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Principal shareholder, Chairman of the Board, President, and Director
Jia Tian (Jeffery) Lin [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Former Chief Executive Officer
Wen-Piao (Jack) Lai [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Director
Shao-Cheng (Will) Wang [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Former Chief Financial Officer
Kuang Ming (James) Tsai [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Director and Chief Financial Officer
Hsin-Ta (Darren) Su [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Director, Treasurer
Hui-Chuan (Sandra) Lin [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Director and Secretary, daughter of Jui Pin (John) Lin
David Tang [Member]  
Related Party Transactions [Line Items]  
Relationship with the Company Chief Executive Officer
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions (Details) - Schedule of Due to Related Parties Balances - USD ($)
Sep. 30, 2023
Sep. 30, 2022
Kuang Ming (James) Tsai [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances $ 20,755
Jui Pin (John) Lin [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances 8,048
Jia Tian (Jeffery) Lin [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances 2,500
Shao-Cheng (Will) Wang [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances 27,600
Wen-Piao (Jack) Lai [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances 22,210
Hsin-Ta (Darren) Su [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances 707 17,189
Hui-Chuan (Sandra) Lin [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances 4,529
David Tang [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances 14,023
Related Party [Member]    
Related Party Transactions [Line Items]    
Due to related parties balances $ 14,730 $ 102,831
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes (Details) - USD ($)
12 Months Ended
Sep. 30, 2023
Sep. 30, 2020
Sep. 30, 2021
Income Taxes [Abstract]      
Penalty amount $ 10,000    
Penalty received     $ 25,000
Income taxes return, percentage   25.00%  
Forgiveness of penalty and interest 7,226    
Total amount of penalty and interest $ 32,226    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.4
Commitments and Contingencies (Details) - USD ($)
12 Months Ended
Sep. 30, 2023
Sep. 30, 2021
Sep. 30, 2020
Commitments and Contingencies [Abstract]      
Operating lease cost $ 200    
Penalty imposed   $ 25,000  
Return, percentage     25.00%
XML 44 f10k2023_genufood_htm.xml IDEA: XBRL DOCUMENT 0001510518 2022-10-01 2023-09-30 0001510518 2024-01-09 0001510518 2023-03-31 0001510518 2023-09-30 0001510518 2022-09-30 0001510518 us-gaap:RelatedPartyMember 2023-09-30 0001510518 us-gaap:RelatedPartyMember 2022-09-30 0001510518 2021-10-01 2022-09-30 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-10-01 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-10-01 2023-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2023-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2023-09-30 0001510518 us-gaap:CommonStockMember 2023-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2023-09-30 0001510518 us-gaap:RetainedEarningsMember 2023-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-11-17 2021-11-17 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 gfoo:HukuiSharesMember 2021-11-19 0001510518 gfoo:HukuiSharesMember 2021-11-01 2021-11-19 0001510518 gfoo:HukuiSharesMember 2022-10-01 2023-09-30 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-19 2021-11-19 0001510518 2023-02-24 0001510518 2023-02-24 2023-02-24 0001510518 2023-03-24 0001510518 2023-03-24 2023-03-24 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-09-30 0001510518 us-gaap:StockOptionMember gfoo:VestingMember 2022-10-01 2023-09-30 0001510518 gfoo:VestingMember 2022-10-01 2023-09-30 0001510518 us-gaap:StockOptionMember 2022-10-01 2023-09-30 0001510518 us-gaap:StockOptionMember 2021-10-01 2022-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2023-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2023-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2023-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2023-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2023-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2023-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2023-09-30 0001510518 gfoo:DavidTangMember 2022-10-01 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2023-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2023-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2023-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2023-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2023-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2023-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:DavidTangMember 2023-09-30 0001510518 gfoo:DavidTangMember 2022-09-30 0001510518 us-gaap:RelatedPartyMember 2023-09-30 0001510518 us-gaap:RelatedPartyMember 2022-09-30 0001510518 2019-10-01 2020-09-30 0001510518 2020-10-01 2021-09-30 shares iso4217:USD iso4217:USD shares gfoo:Segment pure 10-K true 2023-09-30 --09-30 2023 false 000-56112 GENUFOOD ENERGY ENZYMES CORP. NV 68-0681158 1108 S. Baldwin Avenue Suite 107 Arcadia CA 91007 (855) 707-2077 No No Yes Yes Non-accelerated Filer true false false false false 808900041 2851 KCCW Accountancy Corp. California 125924 136400 8187 14493 134111 150893 67451 201562 150893 100849 102185 37 14730 102831 115616 205016 32226 29226 0.001 0.001 10000000000 10000000000 808900041 808900041 299686921 299686921 808900 299687 16989592 16927592 7241581 7241581 -10503191 -9875489 -193558 53720 -83349 201562 150893 432296 348845 432296 348845 -432296 -348845 2 6 -192365 -43 6 -3000 -3835 -195406 -3823 -627702 -352668 -627702 -352668 193558 25 -434144 -352643 526044946 299686921 299686921 299687 16911770 -7241581 -9522821 -193583 253472 15822 15822 -352668 -352668 25 25 299686921 299687 16927592 -7241581 -9875489 -193558 -83349 75000 75000 375000000 375000 -13000 362000 134213120 134213 134213 193643 193643 -627702 -627702 -85 -85 808900041 808900 16989592 -7241581 -10503191 53720 -627702 -352668 75000 15822 -192365 -6306 -11280 -143 1507 37 -1590 46112 99821 3000 3000 -305025 -222828 67451 350000 -67451 350000 362000 362000 -43 -10476 127129 136400 9271 125924 136400 134213 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>NOTE 1 – GENERAL ORGANIZATION AND BUSINESS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which was dissolved on January 9, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the year ended September 30, 2023, the Company has initiated its electric vehicle charging station business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of September 30, 2023, the Company has two sites under construction for charging stations and three sites under planning.</span></p> 80000 800000 60000 600000 140000 350000 2.5 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Principle of Consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Concentrations of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cash and Cash Equivalents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of September 30, 2023, and 2022, the Company did not have cash equivalents. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value of Financial Instruments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"> </span></td> <td style="width: 0.25in"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 3 inputs are less observable and reflect our own assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Foreign Currency Translation and Transactions</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7293 average exchange rates were used to translate revenues and expenses for the year ended September 30, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Business Segments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company operates in only one segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Net Income (Loss) Per Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the years ended September 30, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Discounts on Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Stock-Based Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Income Taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>There were no current and deferred income tax provision recorded for the years ended September 30, 2023 and 2022 since the Company has recurring losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Recent Accounting Pronouncements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basis of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Principle of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cash and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of September 30, 2023, and 2022, the Company did not have cash equivalents. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"> </span></td> <td style="width: 0.25in"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 1 inputs are quoted prices available for identical assets and liabilities in active markets.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 3 inputs are less observable and reflect our own assumptions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Foreign Currency Translation and Transactions</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7293 average exchange rates were used to translate revenues and expenses for the year ended September 30, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying consolidated statements of operations.</span></p> 0.697 0.7293 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Business Segments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company operates in only one segment.</span></p> 1 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Net Income (Loss) Per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the years ended September 30, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Discounts on Common Stock</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>Stock-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>There were no current and deferred income tax provision recorded for the years ended September 30, 2023 and 2022 since the Company has recurring losses.</span></p> 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Recent Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 3 – GOING CONCERN</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of September 30, 2023, and 2022, the Company had an accumulated deficit of $10,503,191 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company sold the 140,000 Hukui Shares for $350,000 in cash on November 19, 2021, and received $362,000 from private placement during the year ended September 30, 2023. The proceeds have been used for operation expenses. Management is currently seeking additional funds for future operation.</span></p> -10503191 -9875489 140000 350000 362000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 4 – EQUIPMENT</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of September 30, 2023, and 2022 the Company had equipment of $67,451 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations and related installation costs.</span></p> 67451 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 5 – INVESTMENT</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment was recorded at cost.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On November 17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.</span></p> 200000 10 2000000 80000 10 800000 60000 10 600000 1400000 0.20 140000 2.5 350000 1050000 1050000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On February 24, 2023, the Company conducted a private placement offering and sold 375,000,000 shares of common stock at $0.001 per share, for gross proceeds of $375,000, and incurred offering costs of $13,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March 24, 2023, the Company issued 134,213,120 shares of common stock to its board of directors, officers, and former officers to repay the compensation due to them in the aggregate amount of $134,213 at the conversion rate of $0.001 per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Stock Options</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of September 30, 2023, total options granted was 15,000,000 and 4,375,000 was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $75,000 and $15,822, respectively, which was included in the general and administrative expenses in the consolidated statements of operations for the years ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.99</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">6.08 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379.35</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The following is a summary of the option activity for the year ended September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Underlying<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at October 1, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">–</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">           –</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">–</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">–</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Vested and expected to vest as of September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,375,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of September 30, 2023<i>,</i> unrecognized total compensation cost associated with these options was $209,178. This expense is expected to be recognized over a weighted-average period of 2.79 years.</span></p> 10000000000 0.001 375000000 0.001 375000 13000 134213120 134213 0.001 15000000 0.01 15000000 4375000 0.25 0.75 10 0.02 75000 15822 <span>The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.99</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">6.08 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379.35</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table> 0.0299 P6Y29D 3.7935 0 <span>The following is a summary of the option activity for the year ended September 30, 2023:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Underlying<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at October 1, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">–</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">           –</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">–</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">–</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">–</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">–</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Vested and expected to vest as of September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable at September 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,375,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.01</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">–</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 15000000 0.01 15000000 0.01 P8Y9M18D 15000000 0.01 P8Y9M18D 4375000 0.01 P8Y9M18D 209178 P2Y9M14D <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 7 – RELATED PARTY TRANSACTIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b><i>Related Parties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-size: 10pt"><b>Name of related parties</b></span></td> <td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; width: 69%"><span style="font-size: 10pt"><b>Relationship with the Company</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Yi Lung (Oliver) Lin</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Principal shareholder</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Jui Pin (John) Lin</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Principal shareholder, Chairman of the Board, President, and Director</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Jia Tian (Jeffery) Lin</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Former Chief Executive Officer</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Wen-Piao (Jack) Lai</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Shao-Cheng (Will) Wang</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Former Chief Financial Officer</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Kuang Ming (James) Tsai</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director and Chief Financial Officer</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Hsin-Ta (Darren) Su</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director, Treasurer</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Hui-Chuan (Sandra) Lin</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director and Secretary, daughter of Jui Pin (John) Lin</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">David Tang</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Due to Related Parties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s due to related parties balances are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Kuang Ming (James) Tsai</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,755</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jui Pin (John) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jia Tian (Jeffery) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Shao-Cheng (Will) Wang</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Wen-Piao (Jack) Lai</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hsin-Ta (Darren) Su</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">707</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,189</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hui-Chuan (Sandra) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">David Tang</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,730</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102,831</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The related party balances are unsecured, interest-free and due on demand.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-size: 10pt"><b>Name of related parties</b></span></td> <td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; width: 69%"><span style="font-size: 10pt"><b>Relationship with the Company</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Yi Lung (Oliver) Lin</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Principal shareholder</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Jui Pin (John) Lin</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Principal shareholder, Chairman of the Board, President, and Director</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Jia Tian (Jeffery) Lin</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Former Chief Executive Officer</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Wen-Piao (Jack) Lai</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Shao-Cheng (Will) Wang</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Former Chief Financial Officer</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Kuang Ming (James) Tsai</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director and Chief Financial Officer</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">Hsin-Ta (Darren) Su</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director, Treasurer</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-size: 10pt">Hui-Chuan (Sandra) Lin</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Director and Secretary, daughter of Jui Pin (John) Lin</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-size: 10pt">David Tang</span></td> <td style="vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr> </table> Principal shareholder Principal shareholder, Chairman of the Board, President, and Director Former Chief Executive Officer Director Former Chief Financial Officer Director and Chief Financial Officer Director, Treasurer Director and Secretary, daughter of Jui Pin (John) Lin Chief Executive Officer <span>The Company’s due to related parties balances are as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Kuang Ming (James) Tsai</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,755</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jui Pin (John) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Jia Tian (Jeffery) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Shao-Cheng (Will) Wang</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Wen-Piao (Jack) Lai</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hsin-Ta (Darren) Su</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">707</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,189</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Hui-Chuan (Sandra) Lin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">David Tang</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,730</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102,831</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 20755 8048 2500 27600 22210 707 17189 4529 14023 14730 102831 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>NOTE 8 – INCOME TAXES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $7,226, for a total of $32,226, which was still pending as of September 30, 2023.</span></p> 10000 25000 0.25 7226 32226 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 9 – COMMITMENTS AND CONTINGENCIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of September 30, 2023, the Company has no material commitments under operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 8).</span></p> 200 25000 0.25 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE 10 – SUBSEQUENT EVENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.</span></p> 299686921 526044946 false FY 0001510518 0 Less than $0.01 per share EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

,"2*['MP[WT4KM]3 MX>;_AZ,_4$L#!!0 ( (YX+%B7BKL

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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 90 193 1 true 24 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://geecenzymes.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://geecenzymes.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://geecenzymes.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) Sheet http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consoildated Statements of Stockholders??? Equity (Deficit) Sheet http://geecenzymes.com/role/ShareholdersEquityType2or3 Consoildated Statements of Stockholders??? Equity (Deficit) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://geecenzymes.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - General Organization and Business Sheet http://geecenzymes.com/role/GeneralOrganizationandBusiness General Organization and Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Going Concern Sheet http://geecenzymes.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 010 - Disclosure - Equipment Sheet http://geecenzymes.com/role/Equipment Equipment Notes 11 false false R12.htm 011 - Disclosure - Investment Sheet http://geecenzymes.com/role/Investment Investment Notes 12 false false R13.htm 012 - Disclosure - Stockholders??? Equity (Deficit) Sheet http://geecenzymes.com/role/StockholdersEquityDeficit Stockholders??? Equity (Deficit) Notes 13 false false R14.htm 013 - Disclosure - Related Party Transactions Sheet http://geecenzymes.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 014 - Disclosure - Income Taxes Sheet http://geecenzymes.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Commitments and Contingencies Sheet http://geecenzymes.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Subsequent Events Sheet http://geecenzymes.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 017 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://geecenzymes.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 018 - Disclosure - Stockholders??? Equity (Deficit) (Tables) Sheet http://geecenzymes.com/role/StockholdersEquityDeficitTables Stockholders??? Equity (Deficit) (Tables) Tables http://geecenzymes.com/role/StockholdersEquityDeficit 19 false false R20.htm 019 - Disclosure - Related Party Transactions (Tables) Sheet http://geecenzymes.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://geecenzymes.com/role/RelatedPartyTransactions 20 false false R21.htm 020 - Disclosure - General Organization and Business (Details) Sheet http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails General Organization and Business (Details) Details http://geecenzymes.com/role/GeneralOrganizationandBusiness 21 false false R22.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 22 false false R23.htm 022 - Disclosure - Going Concern (Details) Sheet http://geecenzymes.com/role/GoingConcernDetails Going Concern (Details) Details http://geecenzymes.com/role/GoingConcern 23 false false R24.htm 023 - Disclosure - Equipment (Details) Sheet http://geecenzymes.com/role/EquipmentDetails Equipment (Details) Details http://geecenzymes.com/role/Equipment 24 false false R25.htm 024 - Disclosure - Investment (Details) Sheet http://geecenzymes.com/role/InvestmentDetails Investment (Details) Details http://geecenzymes.com/role/Investment 25 false false R26.htm 025 - Disclosure - Stockholders??? Equity (Deficit) (Details) Sheet http://geecenzymes.com/role/StockholdersEquityDeficitDetails Stockholders??? Equity (Deficit) (Details) Details http://geecenzymes.com/role/StockholdersEquityDeficitTables 26 false false R27.htm 026 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model Sheet http://geecenzymes.com/role/ScheduleofFairValuetheStockOptionsBlackScholesOptionPricingModelTable Stockholders??? Equity (Deficit) (Details) - Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model Details http://geecenzymes.com/role/StockholdersEquityDeficitTables 27 false false R28.htm 027 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of Option Activity Sheet http://geecenzymes.com/role/ScheduleofOptionActivityTable Stockholders??? Equity (Deficit) (Details) - Schedule of Option Activity Details http://geecenzymes.com/role/StockholdersEquityDeficitTables 28 false false R29.htm 028 - Disclosure - Related Party Transactions (Details) - Schedule of Related Parties Name and Relationship Sheet http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable Related Party Transactions (Details) - Schedule of Related Parties Name and Relationship Details http://geecenzymes.com/role/RelatedPartyTransactionsTables 29 false false R30.htm 029 - Disclosure - Related Party Transactions (Details) - Schedule of Due to Related Parties Balances Sheet http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable Related Party Transactions (Details) - Schedule of Due to Related Parties Balances Details http://geecenzymes.com/role/RelatedPartyTransactionsTables 30 false false R31.htm 030 - Disclosure - Income Taxes (Details) Sheet http://geecenzymes.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://geecenzymes.com/role/IncomeTaxes 31 false false R32.htm 031 - Disclosure - Commitments and Contingencies (Details) Sheet http://geecenzymes.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://geecenzymes.com/role/CommitmentsandContingencies 32 false false All Reports Book All Reports f10k2023_genufood.htm gfoo-20230930.xsd gfoo-20230930_cal.xml gfoo-20230930_def.xml gfoo-20230930_lab.xml gfoo-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f10k2023_genufood.htm": { "nsprefix": "gfoo", "nsuri": "http://geecenzymes.com/20230930", "dts": { "inline": { "local": [ "f10k2023_genufood.htm" ] }, "schema": { "local": [ "gfoo-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] }, "calculationLink": { "local": [ "gfoo-20230930_cal.xml" ] }, "definitionLink": { "local": [ "gfoo-20230930_def.xml" ] }, "labelLink": { "local": [ "gfoo-20230930_lab.xml" ] }, "presentationLink": { "local": [ "gfoo-20230930_pre.xml" ] } }, "keyStandard": 172, "keyCustom": 21, "axisStandard": 8, "axisCustom": 0, "memberStandard": 9, "memberCustom": 14, "hidden": { "total": 83, "http://fasb.org/us-gaap/2023": 72, "http://xbrl.sec.gov/dei/2023": 4, "http://geecenzymes.com/20230930": 7 }, "contextCount": 90, "entityCount": 1, "segmentCount": 24, "elementCount": 288, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 306, "http://xbrl.sec.gov/dei/2023": 35 }, "report": { "R1": { "role": "http://geecenzymes.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R2": { "role": "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R3": { "role": "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "unique": true } }, "R4": { "role": "http://geecenzymes.com/role/ConsolidatedIncomeStatement", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R5": { "role": "http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://geecenzymes.com/role/ShareholdersEquityType2or3", "longName": "005 - Statement - Consoildated Statements of Stockholders\u2019 Equity (Deficit)", "shortName": "Consoildated Statements of Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R7": { "role": "http://geecenzymes.com/role/ConsolidatedCashFlow", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncreaseDecreaseInPrepaidExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "unique": true } }, "R8": { "role": "http://geecenzymes.com/role/GeneralOrganizationandBusiness", "longName": "007 - Disclosure - General Organization and Business", "shortName": "General Organization and Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R9": { "role": "http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R10": { "role": "http://geecenzymes.com/role/GoingConcern", "longName": "009 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R11": { "role": "http://geecenzymes.com/role/Equipment", "longName": "010 - Disclosure - Equipment", "shortName": "Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R12": { "role": "http://geecenzymes.com/role/Investment", "longName": "011 - Disclosure - Investment", "shortName": "Investment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R13": { "role": "http://geecenzymes.com/role/StockholdersEquityDeficit", "longName": "012 - Disclosure - Stockholders\u2019 Equity (Deficit)", "shortName": "Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R14": { "role": "http://geecenzymes.com/role/RelatedPartyTransactions", "longName": "013 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R15": { "role": "http://geecenzymes.com/role/IncomeTaxes", "longName": "014 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R16": { "role": "http://geecenzymes.com/role/CommitmentsandContingencies", "longName": "015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R17": { "role": "http://geecenzymes.com/role/SubsequentEvents", "longName": "016 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R18": { "role": "http://geecenzymes.com/role/AccountingPoliciesByPolicy", "longName": "017 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R19": { "role": "http://geecenzymes.com/role/StockholdersEquityDeficitTables", "longName": "018 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)", "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R20": { "role": "http://geecenzymes.com/role/RelatedPartyTransactionsTables", "longName": "019 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R21": { "role": "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "longName": "020 - Disclosure - General Organization and Business (Details)", "shortName": "General Organization and Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "c35", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c35", "name": "us-gaap:InvestmentOwnedBalanceShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R22": { "role": "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "021 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "c4", "name": "gfoo:AverageExchangeRate", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "gfoo:AverageExchangeRate", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R23": { "role": "http://geecenzymes.com/role/GoingConcernDetails", "longName": "022 - Disclosure - Going Concern (Details)", "shortName": "Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true }, "uniqueAnchor": { "contextRef": "c38", "name": "us-gaap:InvestmentSoldNotYetPurchasedBalanceShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "unique": true } }, "R24": { "role": "http://geecenzymes.com/role/EquipmentDetails", "longName": "023 - Disclosure - Equipment (Details)", "shortName": "Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R25": { "role": "http://geecenzymes.com/role/InvestmentDetails", "longName": "024 - Disclosure - Investment (Details)", "shortName": "Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c52", "name": "us-gaap:SharePrice", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:OtherInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "unique": true } }, "R26": { "role": "http://geecenzymes.com/role/StockholdersEquityDeficitDetails", "longName": "025 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details)", "shortName": "Stockholders\u2019 Equity (Deficit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c52", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c52", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R27": { "role": "http://geecenzymes.com/role/ScheduleofFairValuetheStockOptionsBlackScholesOptionPricingModelTable", "longName": "026 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model", "shortName": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R28": { "role": "http://geecenzymes.com/role/ScheduleofOptionActivityTable", "longName": "027 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Option Activity", "shortName": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Option Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R29": { "role": "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable", "longName": "028 - Disclosure - Related Party Transactions (Details) - Schedule of Related Parties Name and Relationship", "shortName": "Related Party Transactions (Details) - Schedule of Related Parties Name and Relationship", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c61", "name": "us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c61", "name": "us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R30": { "role": "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "longName": "029 - Disclosure - Related Party Transactions (Details) - Schedule of Due to Related Parties Balances", "shortName": "Related Party Transactions (Details) - Schedule of Due to Related Parties Balances", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c71", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c71", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R31": { "role": "http://geecenzymes.com/role/IncomeTaxesDetails", "longName": "030 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CapitalUnitsNetAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CapitalUnitsNetAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } }, "R32": { "role": "http://geecenzymes.com/role/CommitmentsandContingenciesDetails", "longName": "031 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023_genufood.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of shares", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r360", "r362", "r423", "r425", "r430", "r448" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r56", "r445", "r531" ] }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaid", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } }, "auth_ref": [ "r478" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related parties", "verboseLabel": "Due to related parties balances", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r16", "r445" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r75", "r184", "r185", "r437", "r491" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r217" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r98", "r106", "r107", "r108", "r127", "r147", "r148", "r150", "r152", "r155", "r156", "r179", "r186", "r188", "r189", "r190", "r193", "r194", "r197", "r198", "r200", "r203", "r209", "r271", "r339", "r340", "r341", "r342", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r371", "r392", "r415", "r431", "r432", "r433", "r434", "r435", "r464", "r479", "r485" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r23", "r113", "r115", "r121", "r312", "r326" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-operating income (expenses), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r66" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r60", "r84", "r322", "r445", "r480", "r489", "r523" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Forfeited or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r501" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Non-Cash Investing and Financing Activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of segments (in Segment)", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r486" ] }, "us-gaap_InvestmentSoldNotYetPurchasedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentSoldNotYetPurchasedBalanceShares", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company sold shares (in Shares)", "label": "Security Sold Short, Shares", "documentation": "Number of securities sold short (the short position) as of the end of the period." } } }, "auth_ref": [ "r424" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment and contingencies (Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r18", "r49", "r318", "r370" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Business Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r161", "r162", "r163", "r164", "r165", "r166", "r176", "r444" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting right percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r495" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/GoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r57", "r77", "r321", "r332", "r334", "r343", "r372", "r445" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r33", "r34", "r35", "r89", "r90", "r93", "r94" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r278" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r217" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r68" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r445" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r218" ] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of shares purchased", "label": "Investment Owned, Balance, Principal Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": [ "r360", "r362", "r423", "r425", "r430", "r448" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r26", "r68", "r124" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Forfeited or expired", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r219" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r487", "r524" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for debt conversion", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r11", "r20", "r77" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r42", "r43", "r44", "r45", "r361", "r363", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r402", "r403", "r404", "r405", "r408", "r409", "r410", "r411", "r426", "r427", "r428", "r429", "r440", "r446", "r448" ] }, "us-gaap_InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase aggregate shares (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r54", "r55", "r77", "r339", "r415", "r432" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r76", "r126", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r267", "r418", "r420", "r436" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r47", "r48", "r395", "r396", "r399" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "auth_ref": [ "r144", "r212", "r465", "r484" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r395", "r396", "r399" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r131", "r132", "r133", "r154", "r299", "r337", "r359", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r390", "r393", "r394", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r415", "r449" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r102", "r127", "r179", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r258", "r259", "r260", "r271", "r445", "r492", "r526", "r527" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r361", "r363", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r402", "r403", "r404", "r405", "r408", "r409", "r410", "r411", "r426", "r427", "r428", "r429", "r446", "r448" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r68", "r69", "r70" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r457", "r458", "r459", "r461" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://geecenzymes.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r289", "r290", "r291", "r293", "r296", "r345", "r346", "r347", "r397", "r398", "r399", "r419", "r421" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r64", "r394" ] }, "us-gaap_CapitalUnitsNetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsNetAmount", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Penalty amount", "label": "Capital Units, Net Amount", "documentation": "Net amount applicable to investors of capital units or shares." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepayment", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r7" ] }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentQuotedMarketValue", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss of market value", "label": "Equity Method Investment, Quoted Market Value", "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available." } } }, "auth_ref": [ "r178" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r120", "r127", "r158", "r159", "r167", "r170", "r171", "r175", "r176", "r177", "r179", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r271", "r314", "r492" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r157", "r168", "r172", "r174", "r443" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency transaction adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r6", "r9", "r81" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock, net of offering costs", "verboseLabel": "Gross proceeds", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r211", "r292", "r293", "r365", "r366", "r367", "r368", "r369", "r388", "r390", "r422" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r55" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer [Member]", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r487" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTaxAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Tax [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r457", "r458", "r459" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r98", "r106", "r107", "r108", "r127", "r147", "r148", "r150", "r152", "r155", "r156", "r179", "r186", "r188", "r189", "r190", "r193", "r194", "r197", "r198", "r200", "r203", "r209", "r271", "r339", "r340", "r341", "r342", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r371", "r392", "r415", "r431", "r432", "r433", "r434", "r435", "r464", "r479", "r485" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r457", "r458", "r459" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering costs", "label": "Deferred Offering Costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r490" ] }, "us-gaap_ParticipatingPolicyPercentageOfPremiumIncome": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParticipatingPolicyPercentageOfPremiumIncome", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes return, percentage", "label": "Participating Insurance, Percentage of Premium Income", "documentation": "Percentage of participating insurance to premium income." } } }, "auth_ref": [ "r51", "r317" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://geecenzymes.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r297", "r298" ] }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfEquityMethodInvestments", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of Hukui investment", "label": "Proceeds from Sale of Equity Method Investments", "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r5" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r457", "r458", "r459" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r286", "r287" ] }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling shares value", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current", "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer." } } }, "auth_ref": [ "r36" ] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails", "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series C Preferred Stock [Member]", "verboseLabel": "Series C Preferred Shares [Member]", "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r470", "r471", "r494" ] }, "us-gaap_LossOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossOnSaleOfInvestments", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on sale", "label": "Loss on Sale of Investments", "documentation": "The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale." } } }, "auth_ref": [ "r475", "r476", "r477", "r529" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Principle of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r41", "r441" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r88", "r97", "r142", "r143", "r160", "r242", "r253", "r328" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r4", "r276", "r284" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r71", "r125" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "GENERAL ORGANIZATION AND BUSINESS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r52", "r80", "r335", "r336" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r231" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r457", "r458", "r459" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r462" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r31", "r32" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r12", "r13", "r40" ] }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueOffBalanceSheetRisksTextBlock", "presentation": [ "http://geecenzymes.com/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Due to Related Parties Balances", "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined) which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition." } } }, "auth_ref": [ "r46", "r82" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency income (loss)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r273", "r274", "r275", "r277", "r412" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r79" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r21", "r22", "r61", "r109", "r320", "r333", "r334" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income (expense)", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r87" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow", "http://geecenzymes.com/role/ConsolidatedIncomeStatement", "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r63", "r70", "r86", "r100", "r112", "r114", "r119", "r127", "r134", "r136", "r137", "r138", "r139", "r142", "r143", "r149", "r157", "r168", "r172", "r174", "r179", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r270", "r271", "r325", "r391", "r413", "r414", "r443", "r454", "r492" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for debt conversion", "label": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r29", "r30" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of common stock diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r136", "r137", "r138", "r139", "r140", "r147", "r150", "r151", "r152", "r153", "r269", "r270", "r313", "r327", "r442" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r463" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r457", "r458", "r459" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r456" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in- Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r232", "r233", "r234", "r348", "r481", "r482", "r483", "r522", "r532" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Penalty imposed", "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense", "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r521" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://geecenzymes.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r128", "r239", "r244", "r245", "r248", "r252", "r254", "r255", "r256", "r344" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r83", "r105", "r127", "r157", "r169", "r173", "r179", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r257", "r259", "r271", "r316", "r383", "r445", "r455", "r492", "r493", "r526" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related parties", "label": "Increase (Decrease) in Due to Related Parties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "gfoo_ScheduleOfRelatedPartiesNameAndRelationshipAbstract": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ScheduleOfRelatedPartiesNameAndRelationshipAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Related Parties Name And Relationship Abstract" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r456" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r50", "r91" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://geecenzymes.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "terseLabel": "GOING CONCERN", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r53" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r116", "r240", "r241", "r245", "r246", "r247", "r249", "r338" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r20", "r99", "r117", "r118", "r119", "r131", "r132", "r133", "r135", "r141", "r143", "r154", "r180", "r181", "r210", "r232", "r233", "r234", "r250", "r251", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r279", "r280", "r281", "r282", "r283", "r285", "r288", "r329", "r330", "r331", "r348", "r415" ] }, "gfoo_ScheduleOfDueToRelatedPartiesBalancesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ScheduleOfDueToRelatedPartiesBalancesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Due To Related Parties Balances Abstract" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]", "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition." } } }, "auth_ref": [ "r46", "r82" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r99", "r131", "r132", "r133", "r135", "r141", "r143", "r180", "r181", "r232", "r233", "r234", "r250", "r251", "r261", "r263", "r264", "r266", "r268", "r329", "r331", "r348", "r532" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://geecenzymes.com/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Parties Name and Relationship", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "verboseLabel": "Stock based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_EquityMethodInvestmentAggregateCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentAggregateCost", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate investment", "label": "Equity Method Investment, Aggregate Cost", "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r456" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r456" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r231" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (years), Beginning Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r78" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r62", "r85", "r157", "r168", "r172", "r174", "r314", "r324", "r443" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r221" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/EquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r74", "r104", "r323" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (years) Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r222" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r54", "r55", "r77", "r218" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r456" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosures", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity (Deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r55", "r58", "r59", "r72", "r373", "r389", "r416", "r417", "r445", "r455", "r480", "r489", "r523", "r532" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://geecenzymes.com/role/ScheduleofFairValuetheStockOptionsBlackScholesOptionPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r226" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for debt conversion (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r11", "r19", "r37", "r77", "r195" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r315", "r323", "r445" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r456" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r99", "r117", "r118", "r119", "r131", "r132", "r133", "r135", "r141", "r143", "r154", "r180", "r181", "r210", "r232", "r233", "r234", "r250", "r251", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r279", "r280", "r281", "r282", "r283", "r285", "r288", "r329", "r330", "r331", "r348", "r415" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r10", "r22", "r262", "r265", "r288", "r329", "r330", "r472", "r473", "r474", "r481", "r482", "r483" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit, percentage", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r243" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r213", "r214", "r224", "r225", "r226", "r227", "r230", "r235", "r236", "r237", "r238" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r456" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r38" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "General Organization and Business [Abstract]" } } }, "auth_ref": [] }, "gfoo_ScheduleOfFairValueTheStockOptionsBlackScholesOptionPricingModelAbstract": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ScheduleOfFairValueTheStockOptionsBlackScholesOptionPricingModelAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Fair Value the Stock Options Black-Scholes Option Pricing Model [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r448" ] }, "us-gaap_OtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestments", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total investment", "label": "Other Investments", "documentation": "Amount of investments classified as other." } } }, "auth_ref": [ "r469" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r146", "r152" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r220" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding - basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r145", "r152" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Beginning Outstanding", "periodEndLabel": "Aggregate Intrinsic Value, Ending Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Underlying Shares, Beginning Outstanding", "periodEndLabel": "Number of Underlying Shares, Ending Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r215", "r216" ] }, "gfoo_ScheduleOfOptionActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ScheduleOfOptionActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Option Activity Abstract" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, Beginning Outstanding", "periodEndLabel": "Weighted average exercise price, Ending Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r215", "r216" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award", "documentation": "Description of terms of award under share-based payment arrangement." } } }, "auth_ref": [ "r39" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://geecenzymes.com/role/ScheduleofFairValuetheStockOptionsBlackScholesOptionPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r227" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity (Deficit)", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://geecenzymes.com/role/ScheduleofFairValuetheStockOptionsBlackScholesOptionPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r228" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation and Transactions", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r272" ] }, "gfoo_DiscountsOnCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "DiscountsOnCommonStock", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Discount on common stock", "documentation": "Discount on common stock.", "label": "Discounts On Common Stock" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of shares", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "gfoo_HuiChuanSandraLinMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "HuiChuanSandraLinMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Hui-Chuan (Sandra) Lin [Member]", "label": "Hui Chuan Sandra Lin Member" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "auth_ref": [ "r144", "r212", "r465", "r466", "r484" ] }, "gfoo_CommonStockIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "CommonStockIssued", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued", "documentation": "The amount of common stock issued.", "label": "Common Stock Issued" } } }, "auth_ref": [] }, "gfoo_HukuiAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "HukuiAgreementMember", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hukui Agreement [Member]", "label": "Hukui Agreement Member" } } }, "auth_ref": [] }, "gfoo_InvestmentDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "InvestmentDetailsTable", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Investment (Details) [Table]" } } }, "auth_ref": [] }, "gfoo_HukuiBiotechnologyCorporationHukuiMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "HukuiBiotechnologyCorporationHukuiMember", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hukui Biotechnology Corporation (\u201cHukui\u201d) [Member]", "label": "Hukui Biotechnology Corporation Hukui Member" } } }, "auth_ref": [] }, "gfoo_CommonStockIssuedinShares": { "xbrltype": "sharesItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "CommonStockIssuedinShares", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued (in Shares)", "documentation": "Number of shares common stock issued.", "label": "Common Stock Issuedin Shares" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://geecenzymes.com/role/ScheduleofFairValuetheStockOptionsBlackScholesOptionPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r223" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash consideration", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of Hukui investment", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r24" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r55" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of September 30, 2023 and September 30, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r55", "r319", "r445" ] }, "gfoo_EquipmentDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "EquipmentDetailsLineItems", "presentation": [ "http://geecenzymes.com/role/EquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment [Abstract]", "label": "Equipment Details Line Items" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r110", "r182", "r183", "r439" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r223" ] }, "gfoo_InvestmentDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "InvestmentDetailsLineItems", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Investment (Details) [Line Items]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails", "http://geecenzymes.com/role/InvestmentDetails", "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "gfoo_DisposalOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "DisposalOfSubsidiary", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of subsidiary", "documentation": "The amount of disposal of subsidiary.", "label": "Disposal Of Subsidiary" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "gfoo_JuiPinJohnLinMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "JuiPinJohnLinMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Jui Pin (John) Lin [Member]", "label": "Jui Pin John Lin Member" } } }, "auth_ref": [] }, "gfoo_PurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "PurchasePrice", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "documentation": "The amount of purchase price.", "label": "Purchase Price" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase shares of stock (in Shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r54", "r197" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r55", "r371" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r55", "r371", "r389", "r532", "r533" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r223" ] }, "us-gaap_InvestmentIssuerNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerNameAxis", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Issuer Name [Axis]", "documentation": "Information by name of issuer of investment." } } }, "auth_ref": [ "r534", "r535", "r536", "r537" ] }, "gfoo_IncreaseDecreaseIncommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "IncreaseDecreaseIncommitmentsAndContingencies", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment and contingencies", "documentation": "Commitment and contingencies.", "label": "Increase Decrease Incommitments And Contingencies" } } }, "auth_ref": [] }, "gfoo_JiaTianJefferyLinMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "JiaTianJefferyLinMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Jia Tian (Jeffery) Lin [Member]", "label": "Jia Tian Jeffery Lin Member" } } }, "auth_ref": [] }, "gfoo_PercentageOfEquityInvestment": { "xbrltype": "percentItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "PercentageOfEquityInvestment", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of equity investment", "label": "Percentage Of Equity Investment" } } }, "auth_ref": [] }, "gfoo_KuangMingJamesTsaiMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "KuangMingJamesTsaiMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Kuang Ming (James) Tsai [Member]", "label": "Kuang Ming James Tsai Member" } } }, "auth_ref": [] }, "gfoo_HukuiSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "HukuiSharesMember", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hukui Shares [Member]", "label": "Hukui Shares Member" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails", "http://geecenzymes.com/role/InvestmentDetails", "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r292", "r293", "r525" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "gfoo_SaleOfSharesDuringTheTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "SaleOfSharesDuringTheTransaction", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling aggregate shares (in Shares)", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Shares During The Transaction" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r481", "r482", "r522", "r530", "r532" ] }, "gfoo_PurchaseOfAdditionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "PurchaseOfAdditionalShares", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of additional shares (in Shares)", "documentation": "Purchase of additional shares.", "label": "Purchase Of Additional Shares" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r67" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16" ] }, "gfoo_DiscountsOnCommonStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "DiscountsOnCommonStockPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Discounts on Common Stock", "documentation": "Disclosure of accounting policy for discounts on common stock.", "label": "Discounts On Common Stock Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forgiveness of penalty and interest", "label": "Income Tax Examination, Penalties and Interest Expense", "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations." } } }, "auth_ref": [ "r521" ] }, "gfoo_ShaoChengWillWangMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ShaoChengWillWangMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shao-Cheng (Will) Wang [Member]", "label": "Shao Cheng Will Wang Member" } } }, "auth_ref": [] }, "gfoo_GoingConcernDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "GoingConcernDetailsTable", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Going Concern (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total amount of penalty and interest", "label": "Income Tax Examination, Penalties and Interest Accrued", "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations." } } }, "auth_ref": [ "r521" ] }, "gfoo_EquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "EquipmentTable", "presentation": [ "http://geecenzymes.com/role/Equipment" ], "lang": { "en-us": { "role": { "label": "Equipment [Table]" } } }, "auth_ref": [] }, "gfoo_AverageExchangeRates": { "xbrltype": "perShareItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "AverageExchangeRates", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average exchange rates", "label": "Average Exchange Rates" } } }, "auth_ref": [] }, "gfoo_IncomeTaxesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "IncomeTaxesDetailsLineItems", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Abstract]", "label": "Income Taxes Details Line Items" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://geecenzymes.com/role/InvestmentDetails", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in Dollars per share)", "verboseLabel": "Conversion per share", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "gfoo_VestingMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "VestingMember", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Member]", "label": "Vesting Member" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNetAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "gfoo_EquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "EquipmentLineItems", "presentation": [ "http://geecenzymes.com/role/Equipment" ], "lang": { "en-us": { "role": { "label": "Equipment [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "gfoo_StockholdersEquityDeficitDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "StockholdersEquityDeficitDetailsLineItems", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) [Line Items]" } } }, "auth_ref": [] }, "gfoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToPurchaseShares": { "xbrltype": "sharesItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToPurchaseShares", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted options", "documentation": "Share based compensation arrangement by share based payment award options granted to purchase shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted To Purchase Shares" } } }, "auth_ref": [] }, "gfoo_StockholdersEquityDeficitDetailsScheduleofOptionActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "StockholdersEquityDeficitDetailsScheduleofOptionActivityLineItems", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "label": "Schedule of the Option Activity [Abstract]" } } }, "auth_ref": [] }, "gfoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVest": { "xbrltype": "sharesItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVest", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares Vested and expected to vest", "documentation": "Number of underlying shares vested and expected to vest.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Vested And Expected To Vest" } } }, "auth_ref": [] }, "gfoo_YiLungOliverLinMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "YiLungOliverLinMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Yi Lung (Oliver) Lin [Member]", "label": "Yi Lung Oliver Lin Member" } } }, "auth_ref": [] }, "gfoo_StockholdersEquityDeficitDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "StockholdersEquityDeficitDetailsTable", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r71" ] }, "gfoo_StockIssuedDuringValueIssuanceOfCommonStockForDebtConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "StockIssuedDuringValueIssuanceOfCommonStockForDebtConversion", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount", "documentation": "The amount of stock issued during value issuance of common stock for debt conversion.", "label": "Stock Issued During Value Issuance Of Common Stock For Debt Conversion" } } }, "auth_ref": [] }, "gfoo_StockholdersEquityDeficitDetailsScheduleofOptionActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "StockholdersEquityDeficitDetailsScheduleofOptionActivityTable", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Option Activity [Table]" } } }, "auth_ref": [] }, "gfoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToPurchaseSharesPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToPurchaseSharesPricePerShare", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options per share", "documentation": "Share based compensation arrangement by share based payment award options granted to purchase share price share.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted To Purchase Shares Price Per Share" } } }, "auth_ref": [] }, "gfoo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (years), Ending Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r26", "r103", "r438" ] }, "gfoo_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceVestedAndExpectedToVest": { "xbrltype": "perShareItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceVestedAndExpectedToVest", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price Vested and expected to vest", "documentation": "Weighted average exercise price vested and expected to vest.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Exercise Price Vested And Expected To Vest" } } }, "auth_ref": [] }, "gfoo_IncomeTaxesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "IncomeTaxesDetailsTable", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOrLossOnSaleOfStockInSubsidiary", "crdr": "credit", "calculation": { "http://geecenzymes.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow", "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on disposal of subsidiary", "negatedLabel": "Loss on disposal of subsidiary", "label": "Gain (Loss) on Disposition of Stock in Subsidiary", "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries." } } }, "auth_ref": [ "r475", "r476", "r477", "r528" ] }, "us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfCommonOwnershipOrManagementControlRelationships", "presentation": [ "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship with the Company", "label": "Nature of Common Ownership or Management Control Relationships", "documentation": "This element represents a description of the nature of common ownership or management control relationships with other entities, regardless of there being transactions between the entities, when the existence of that control could result in operating results or financial position of the reporting entity significantly different from that which would have been obtained if the entities' were autonomous." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://geecenzymes.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r27" ] }, "gfoo_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualLifeyearsExercisable": { "xbrltype": "durationItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualLifeyearsExercisable", "presentation": [ "http://geecenzymes.com/role/ScheduleofOptionActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (years), Exercisable", "documentation": "Weighted average remaining contractual life (years), exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Lifeyears Exercisable" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://geecenzymes.com/role/Equipment" ], "lang": { "en-us": { "role": { "terseLabel": "EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r73", "r92", "r95", "r96" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://geecenzymes.com/role/Investment" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENT", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r467", "r468", "r488" ] }, "gfoo_GeneralOrganizationandBusinessDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "GeneralOrganizationandBusinessDetailsTable", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "label": "General Organization and Business (Details) [Table]" } } }, "auth_ref": [] }, "gfoo_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "gfoo_PenaltyReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "PenaltyReceived", "crdr": "credit", "presentation": [ "http://geecenzymes.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Penalty received", "documentation": "The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.", "label": "Penalty Received" } } }, "auth_ref": [] }, "gfoo_WenPiaoJackLaiMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "WenPiaoJackLaiMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Wen-Piao (Jack) Lai [Member]", "label": "Wen Piao Jack Lai Member" } } }, "auth_ref": [] }, "gfoo_GeneralOrganizationandBusinessDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "GeneralOrganizationandBusinessDetailsLineItems", "presentation": [ "http://geecenzymes.com/role/GeneralOrganizationandBusinessDetails" ], "lang": { "en-us": { "role": { "label": "General Organization and Business [Line Items]" } } }, "auth_ref": [] }, "gfoo_AverageExchangeRate": { "xbrltype": "perShareItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "AverageExchangeRate", "presentation": [ "http://geecenzymes.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange rate", "documentation": "Average exchange rates.", "label": "Average Exchange Rate" } } }, "auth_ref": [] }, "gfoo_DavidTangMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "DavidTangMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "David Tang [Member]", "label": "David Tang Member" } } }, "auth_ref": [] }, "gfoo_GoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "GoingConcernAbstract", "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r101", "r111", "r127", "r179", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r257", "r259", "r271", "r445", "r492", "r493", "r526" ] }, "gfoo_GoingConcernDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "GoingConcernDetailsLineItems", "presentation": [ "http://geecenzymes.com/role/GoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Going Concern (Details) [Line Items]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "gfoo_RateOfReturnPercentage": { "xbrltype": "percentItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "RateOfReturnPercentage", "presentation": [ "http://geecenzymes.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Return, percentage", "documentation": "Information rate of return percentage.", "label": "Rate Of Return Percentage" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://geecenzymes.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of common stock - basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r136", "r137", "r138", "r139", "r140", "r145", "r147", "r150", "r151", "r152", "r153", "r269", "r270", "r313", "r327", "r442" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r211", "r292", "r293", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r365", "r366", "r367", "r368", "r369", "r388", "r390", "r422", "r525" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://geecenzymes.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "verboseLabel": "Related Party [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r129", "r130", "r292", "r293", "r294", "r295", "r365", "r366", "r367", "r368", "r369", "r388", "r390", "r422" ] }, "gfoo_DiscountOnCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "DiscountOnCommonStockMember", "presentation": [ "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Discount on common stock", "label": "Discount On Common Stock Member" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://geecenzymes.com/role/ConsolidatedBalanceSheet", "http://geecenzymes.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r131", "r132", "r133", "r154", "r299", "r337", "r359", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r390", "r393", "r394", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r415", "r449" ] }, "gfoo_EquipmentDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "EquipmentDetailsTable", "presentation": [ "http://geecenzymes.com/role/EquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Equipment (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r123" ] }, "gfoo_HsinTaDarrenSuMember": { "xbrltype": "domainItemType", "nsuri": "http://geecenzymes.com/20230930", "localname": "HsinTaDarrenSuMember", "presentation": [ "http://geecenzymes.com/role/ScheduleofDuetoRelatedPartiesBalancesTable", "http://geecenzymes.com/role/ScheduleofRelatedPartiesNameandRelationshipTable" ], "lang": { "en-us": { "role": { "terseLabel": "Hsin-Ta (Darren) Su [Member]", "label": "Hsin Ta Darren Su Member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://geecenzymes.com/role/StockholdersEquityDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche One [Member]", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://geecenzymes.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://geecenzymes.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r123" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.12)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "50", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479756/944-50-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(14)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r464": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r466": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 52 0001213900-24-003308-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-003308-xbrl.zip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end